{"e8acc4ef5c9d95b8a975661390f18d3b8701bb96": [["The dire, catastrophic, dystopian reality of people being infected, contaminated, falling ill, and dying is real, almost too real.", [["falling ill", "DISEASE", 82, 93], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["catastrophic", "OBSERVATION_MODIFIER", 10, 22], ["infected", "OBSERVATION", 58, 66]]], ["At the same time, lots of folks insist that it is hoax, a conspiracy, that it is not as bad as people think.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101]]], ["No one is sure how it will end as many or most of us stay at home, self-distancing, self-quarantining, and self-reflecting on what it all means.IntroductionI'm thinking a lot these days about the priorities, resources, decision-making, and political handling and framing of the Covid-19 pandemic in real time.", [["the Covid", "TEST", 274, 283]]], ["I'm thinking of the normative, representative, hegemonic democracy that we all know, live, and experience, the one with constrained elections, limited political parties, corporatized media jingoism, neoliberal education, and weakly encouraged citizen participation outside of the prescribed framework (see Carr and Th\u00e9s\u00e9e 2019) .IntroductionI consume far too much mainstream media and am confronted with and by it even when I do not consume it.", [["neoliberal education", "TREATMENT", 199, 219]]], ["It is everywhere; the ideas, concepts, personalities, and messages are disseminated widely, broadly, swiftly, and unquestionably throughout all platforms, infused into family discussions, community dialogue, and political discourse, and then pushed through the educational meat grinder.", [["meat", "ORGANISM", 273, 277]]], ["Not by everyone, of course, and there is enormous solidarity and wonderful, transformative work, engagement, and change happening around the world.", [["enormous", "OBSERVATION_MODIFIER", 41, 49], ["solidarity", "OBSERVATION", 50, 60]]], ["But the formal sectors-the fundamental governmental structures, the international organizations, and the education systems-are also (or should be) required to create a more meaningful, critically engaged democracy.IntroductionCovid-19 and the Economy I'm particularly interested at this time in how the economy, despite clearly obvious health efforts, concerns, and evidence, continues to shape, pervade, and overarch the context of the pandemic we are facing.", [["IntroductionCovid", "TREATMENT", 214, 231]]], ["However, a quick perusing of the media can provide a rough sketch or environmental scan of how health/survival is being trumped (please excuse the inadvertent pun) by investor/economic interests.IntroductionThere are so many reports, media outlets, platforms, sources and producers (vloggers, bloggers, citizen journalists), and types of engagement that it would be quite easy to get lost in the sea of distortion and messaging.", [["environmental scan", "TEST", 69, 87]]], ["I am not, in any way here, trying to diminish the real, tangible, and material concerns of working people, who are enmeshed in the complete meltdown of entire sectors of the economy, including tourism, hospitality, the arts and culture, and airlines.", [["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["culture", "TEST", 228, 235]]], ["The vulnerable are more vulnerable than ever of contracting the virus, of sustaining satisfactory living conditions, and of influencing 'democracy'.IntroductionAt first glance, foregrounding the pandemic is the extreme attention paid to the stock market.", [["vulnerable", "OBSERVATION_MODIFIER", 4, 14], ["more vulnerable", "OBSERVATION_MODIFIER", 19, 34], ["virus", "OBSERVATION", 64, 69]]], ["Leading the charge, the US Secretary of the Treasury, Steve Mnuchin, believes that the 'coronavirus pandemic [is] \"a great investment opportunity\"' (Forgey 2020) .", [["coronavirus", "DISEASE", 88, 99], ["coronavirus", "ORGANISM", 88, 99]]], ["This is a short-term issue.", [["a short-term issue", "PROBLEM", 8, 26], ["short-term", "OBSERVATION_MODIFIER", 10, 20]]], ["'You know, I look back at people who bought stocks after the crash in 1987, people who bought stocks after the financial crisis,' he continued.", [["people", "ORGANISM", 26, 32], ["people", "ORGANISM", 76, 82], ["people", "SPECIES", 26, 32], ["people", "SPECIES", 76, 82]]], ["(Forgey 2020) The personal wealth-aggrandizement carousel can be exemplified by a Democracy Now (2020b) report on how several US senators used confidential briefings to exploit their personal stock portfolios.IntroductionCalls are growing for a number of U.S. senators to resign, following reports they sold millions of dollars' worth of stocks after receiving privileged briefings about the threat of coronavirus to the global economy.", [["coronavirus", "DISEASE", 402, 413], ["coronavirus", "ORGANISM", 402, 413], ["coronavirus", "PROBLEM", 402, 413], ["coronavirus", "OBSERVATION", 402, 413]]], ["At the time, he had access to classified information about the coronavirus and was receiving daily intelligence briefings.", [["coronavirus", "DISEASE", 63, 74], ["coronavirus", "ORGANISM", 63, 74], ["the coronavirus", "PROBLEM", 59, 74], ["daily intelligence briefings", "TREATMENT", 93, 121]]], ["The stock market began plummeting a week after Burr's sales and has since lost about 30% of its value.", [["Burr's sales", "TREATMENT", 47, 59], ["stock market", "OBSERVATION", 4, 16]]], ["(Democracy Now 2020b) A New York Times report unveils nefarious business dealings in which a company in Germany working on the coronavirus vaccine is being surveilled for a potential takeover by US interests, 'prompting German politicians to insist no country should have a monopoly on any future vaccine' (Reuters 2020) .", [["coronavirus", "DISEASE", 127, 138], ["coronavirus", "ORGANISM", 127, 138], ["coronavirus", "SPECIES", 127, 138], ["the coronavirus vaccine", "TREATMENT", 123, 146]]], ["We can add to this the twisted nature of financial hegemony with the example how 'Italians found on way to 3D print key ventilator piece for $1 to help battle coronavirus-so the company with the patent is threatening to sue':IntroductionAfter two Italian volunteers used a 3-D printer to manufacture a desperately needed ventilator component for those stricken by the coronavirus, the medical company with the patent for the device threatened to sue-even as the printed valves saved at least 10 people's lives in a hospital in the northern Italian city of Brescia.", [["coronavirus", "ORGANISM", 159, 170], ["volunteers", "ORGANISM", 255, 265], ["coronavirus", "ORGANISM", 368, 379], ["valves", "PATHOLOGICAL_FORMATION", 470, 476], ["people", "SPECIES", 495, 501], ["ventilator piece", "TREATMENT", 120, 136], ["coronavirus", "PROBLEM", 159, 170], ["a 3-D printer", "TREATMENT", 271, 284], ["ventilator component", "TREATMENT", 321, 341], ["the device", "TREATMENT", 421, 431], ["the printed valves", "TREATMENT", 458, 476], ["patent", "OBSERVATION", 195, 201], ["patent", "OBSERVATION", 410, 416], ["valves", "ANATOMY", 470, 476], ["Brescia", "ANATOMY", 556, 563]]], ["(Higgens 2020) Concurrently, measures are being taken that explicitly indicate that a free-market, investor-based political culture is ill-prepared to protect the people.", [["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169], ["political culture", "TEST", 114, 131]]], ["For instance, '[t]he Ministry of Health in Prime Minister Pedro S\u00e1nchez's administration on Monday announced it would put all of Spain's private health providers and their facilities into public control as the spread of COVID-19 continues to grip the country' (Payne 2020) .", [["COVID", "TEST", 220, 225]]], ["Questioning if the private sector can adequately respond to the healthcare needs of the populace, not only during pandemics but also at all times, should not be a theoretical question.IntroductionThe mainstream media culture, meshed with evasive normative political structures, also lays bare the foolhardiness of what is truly important.", [["The mainstream media culture", "TEST", 196, 224], ["political structures", "OBSERVATION", 256, 276]]], ["At the same time, military campaigns continue; arms are manufactured, sold, purchased, and used.", [["military campaigns", "TREATMENT", 18, 36]]], ["Military conflict has not stopped, neither have blockades, embargoes, and sanctions, ensuring that the coronavirus will undoubtedly affect a plethora of innocent victims.IntroductionPilkington (2020) of The Guardian exposes how 'US sales of guns and ammunition soar amid coronavirus panic buying.'", [["coronavirus", "DISEASE", 103, 114], ["coronavirus panic", "DISEASE", 271, 288], ["coronavirus", "ORGANISM", 103, 114], ["coronavirus", "ORGANISM", 271, 282], ["coronavirus", "SPECIES", 271, 282], ["the coronavirus", "PROBLEM", 99, 114], ["conflict", "OBSERVATION", 9, 17]]], ["The focus is not on respirators, hospital beds, and trained staff for many.IntroductionLarry Hyatt, owner of one of the country's largest gun shops, Hyatt Guns in Charlotte, North Carolina, told the Guardian that the scenes of mass buying at his store were virtually unprecedented.", [["mass", "PROBLEM", 227, 231], ["mass", "OBSERVATION", 227, 231]]], ["'This is only the second time in my 61 years of business that we've seen anything like this,' he said, adding that the first occasion was the aftermath of the mass shooting at Sandy Hook elementary school in Connecticut in 2012\u2026.", [["the mass", "PROBLEM", 155, 163], ["mass", "OBSERVATION", 159, 163]]], ["There was almost no interest in hunting rifles.", [["no", "UNCERTAINTY", 17, 19], ["interest", "OBSERVATION_MODIFIER", 20, 28], ["hunting rifles", "OBSERVATION", 32, 46]]], ["Instead, people were opting for target guns and there was big demand for AR-15 semi-automatic assault-style rifles.", [["people", "ORGANISM", 9, 15], ["AR", "PROTEIN", 73, 75], ["people", "SPECIES", 9, 15], ["AR", "PROBLEM", 73, 75]]], ["Asked why he thought the spike was happening, Hyatt replied: 'Financial meltdown, pandemic, crime, politics \u2026 you throw it all into the pot, and you have one hell of a mess.'", [["the spike", "PROBLEM", 21, 30]]], ["(Pilkington 2020) The bailout pressure is enormous at this time to soften the potential collapse of capitalist foundations.", [["The bailout pressure", "TREATMENT", 18, 38], ["enormous", "OBSERVATION_MODIFIER", 42, 50], ["collapse", "OBSERVATION", 88, 96]]], ["We all remember the disastrous stimulus package of the Obama administration's first term, in which bankers largely profited to the behest of working people (Taibbi 2013 ).", [["people", "ORGANISM", 149, 155], ["people", "SPECIES", 149, 155]]], ["The rhetoric is already leaning toward massive amounts that may not fully assist or alter the already highly inequitable equation that places may people in debt, in poverty, and in a state of hopelessness.", [["hopelessness", "DISEASE", 192, 204], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["hopelessness", "PROBLEM", 192, 204]]], ["Tankersley and Casselman (2020) , in a New York Times report, highlight the disproportionate ramifications of what is likely to transpire:IntroductionTo blunt the fallout, Washington is weighing proposals that could easily top $2 trillion, a staggering jump from the initial $8.3 billion virus response bill lawmakers approved this month.", [["a staggering jump", "PROBLEM", 240, 257]]], ["Payments to large companies could prove trickier.", [["large", "OBSERVATION_MODIFIER", 12, 17]]], ["The four biggest American airlines collectively bought back $39 billion in stock from 2015 to 2019 and paid out $6 billion in dividends, according to data from Capital IQ.", [["biggest", "OBSERVATION_MODIFIER", 9, 16]]], ["(Tankersley and Casselman 2020) At the same time, 'banks pressure healthcare firms to raise prices on critical drugs, medical supplies for coronavirus':IntroductionIN RECENT WEEKS, investment bankers have pressed health care companies on the front lines of fighting the novel coronavirus, including drug firms developing experimental treatments and medical supply firms, to consider ways that they can profit from the crisis.", [["coronavirus", "DISEASE", 139, 150], ["coronavirus", "DISEASE", 276, 287], ["coronavirus", "ORGANISM", 276, 287], ["'banks pressure healthcare firms", "TREATMENT", 50, 82], ["critical drugs", "TREATMENT", 102, 116], ["medical supplies", "TREATMENT", 118, 134], ["coronavirus", "PROBLEM", 139, 150], ["the novel coronavirus", "PROBLEM", 266, 287], ["experimental treatments", "TREATMENT", 321, 344], ["medical supply firms", "TREATMENT", 349, 369]]], ["The media has mostly focused on individuals who have taken advantage of the market for now-scarce medical and hygiene supplies to hoard masks and hand sanitizer and resell them at higher prices.", [["hand", "ANATOMY", 146, 150], ["hand", "ORGANISM_SUBDIVISION", 146, 150], ["masks", "TREATMENT", 136, 141], ["hand sanitizer", "TREATMENT", 146, 160]]], ["But the largest voices in the health care industry stand to gain from billions of dollars in emergency spending on the pandemic, as do the bankers and investors who invest in health care companies.IntroductionOver the past few weeks, investment bankers have been candid on investor calls and during health care conferences about the opportunity to raise drug prices.", [["largest", "OBSERVATION_MODIFIER", 8, 15]]], ["In some cases, bankers received sharp rebukes from health care executives; in others, executives joked about using the attention on Covid-19 to dodge public pressure on the opioid crisis.", [["Covid", "TREATMENT", 132, 137], ["the opioid crisis", "TREATMENT", 169, 186], ["opioid crisis", "OBSERVATION", 173, 186]]], ["Coronavirus is leaving them in limbo' (Chiu and Saba 2020) .", [["Coronavirus", "PROBLEM", 0, 11]]], ["At a time when all countries are closing borders, limiting or preventing immigration, even tourism, and when there is extreme concern about the transmission of the virus, it seems odd, if not outright totally disjointed, that Canada, and it is probably not the only country in this position, would seek out workers from the Global South to work for a minimal amount when there is no doubt that unemployment will be on the rise at home.", [["the virus", "PROBLEM", 160, 169], ["no doubt", "UNCERTAINTY", 380, 388]]], ["Can we eat only if wages are low for the people bringing it to our tables?", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["Yet, it would appear that, as has been the ritual in past crises as so eloquently presented by Naomi Klein in relation to the shock doctrine during capitalist crises, some people, elites, groups, and interests are taking advantage of the situation, or are preparing to do so (Democracy Now 2020a).", [["shock", "DISEASE", 126, 131], ["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178], ["the shock doctrine", "TREATMENT", 122, 140]]], ["Why do societies continue to uphold social inequalities while also presenting strategies to stem the tide of Covid-19?", [["Covid", "TEST", 109, 114]]], ["Maintaining these social inequalities makes no economic sense, yet changing the systems, structures, and values that underpin them is a spectacularly arduous and debilitating task.ConclusionAn example that troubles and disrupts my thinking is the Canadian Prime Minister Justin Trudeau's principled stand at present, arguing that '[n]o one should have to worry about paying rent, buying groceries, or additional child care because of COVID-19.", [["a spectacularly arduous and debilitating task", "PROBLEM", 134, 179], ["COVID", "TEST", 434, 439]]], ["I agree fullheartedly and would also agree that this should not be the case when there is no pandemic.", [["pandemic", "PROBLEM", 93, 101], ["no", "UNCERTAINTY", 90, 92]]], ["The case is made over and over that resources are too limited to assist those facing the greatest challenges, yet, during a time of crisis, the will to find these resources is significant.ConclusionIn sum, the economy is important.", [["crisis", "PROBLEM", 132, 138]]], ["If and when we make it through the Covid-19 tunnel, it will be important to allow for a reimagining of democracy, sharing resources, and social solidarity.", [["the Covid-19 tunnel", "TREATMENT", 31, 50]]], ["But the potential to work together, across identities, borders, experiences, and philosophies to achieve a more global assessment, engagement, and solidarity to confront global challenges, such as pandemics, and, notably, the environment, should be a worthy and necessary political project.", [["pandemics", "DISEASE", 197, 206], ["a more global assessment", "TEST", 105, 129]]]], "1768d0227d17da88900751bc02acd3887e9daea5": [["| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONWe are all struggling to understand the human catastrophe of the coronavirus disease-2019 (COVID- 19) epidemic.", [["coronavirus disease", "DISEASE", 114, 133], ["human", "ORGANISM", 89, 94], ["coronavirus", "ORGANISM", 114, 125], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["the coronavirus disease", "PROBLEM", 110, 133], ["COVID", "TEST", 140, 145], ["epidemic", "PROBLEM", 151, 159], ["coronavirus", "ANATOMY", 114, 125]]], ["As of , there were 557043 cases of documented COVID-19 infection in the United States, and 21952 deaths.", [["infection", "DISEASE", 55, 64], ["deaths", "DISEASE", 97, 103], ["COVID", "TEST", 46, 51], ["infection", "OBSERVATION", 55, 64]]], ["1 Our economy except for limited sectors has come to a complete halt as we practice physical distancing to try to mitigate the effects of the pandemic.| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONIn the 10 weeks since COVID-19 began to accelerate, there has been a flurry of information from corners expected and unexpected to help us with this understanding.", [["the pandemic", "PROBLEM", 138, 150], ["COVID", "TEST", 182, 187], ["COVID", "TEST", 222, 227]]], ["Rapid publication of peerreviewed data has defined the possible risk factors for COVID-19, its clinical course, and its possible epidemiology.", [["COVID", "TEST", 81, 86]]], ["In this unusual time of a public health emergency, numerous non-peer-reviewed manuscripts have been uploaded to preprint servers, and their unreviewed data and conclusions must be evaluated in this spirit.| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONNevertheless, data both published and in preprint form point to a tantalizing hypothesis: that COVID-19 infection and its severity can be explained by the concentration of glycosylated severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) viral particles in the lung epithe-receptor 2 (ACE2) in the lung epithelium, and the degree and control of the pulmonary immune response to the SARS-CoV-2 spike protein at approximately day 8 to 10 after symptom onset, which may be related to both.", [["lung", "ANATOMY", 523, 527], ["lung epithelium", "ANATOMY", 560, 575], ["pulmonary", "ANATOMY", 611, 620], ["COVID-19", "CHEMICAL", 349, 357], ["infection", "DISEASE", 358, 367], ["acute respiratory syndrome-coronavirus", "DISEASE", 446, 484], ["COVID-19", "ORGANISM", 349, 357], ["severe acute respiratory syndrome-coronavirus 2", "ORGANISM", 439, 486], ["SARS-CoV-2", "ORGANISM", 488, 498], ["lung", "ORGAN", 523, 527], ["epithe-receptor 2", "GENE_OR_GENE_PRODUCT", 528, 545], ["ACE2", "GENE_OR_GENE_PRODUCT", 547, 551], ["lung epithelium", "TISSUE", 560, 575], ["pulmonary", "ORGAN", 611, 620], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 644, 654], ["ACE2", "PROTEIN", 219, 223], ["lung epithe-receptor 2", "PROTEIN", 523, 545], ["ACE2", "PROTEIN", 547, 551], ["SARS-CoV-2 spike protein", "PROTEIN", 644, 668], ["-coronavirus", "SPECIES", 472, 484], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 439, 484], ["COVID", "TEST", 236, 241], ["COVID", "TEST", 349, 354], ["infection", "PROBLEM", 358, 367], ["glycosylated severe acute respiratory syndrome", "PROBLEM", 426, 472], ["coronavirus", "PROBLEM", 473, 484], ["SARS", "TEST", 488, 492], ["CoV", "TEST", 493, 496], ["viral particles", "PROBLEM", 500, 515], ["the pulmonary immune response", "PROBLEM", 607, 636], ["the SARS", "TEST", 640, 648], ["CoV", "TEST", 649, 652], ["2 spike protein", "PROBLEM", 653, 668], ["infection", "OBSERVATION", 358, 367], ["severe", "OBSERVATION_MODIFIER", 439, 445], ["acute", "OBSERVATION_MODIFIER", 446, 451], ["respiratory syndrome", "OBSERVATION", 452, 472], ["viral particles", "OBSERVATION", 500, 515], ["lung", "ANATOMY", 523, 527], ["lung", "ANATOMY", 560, 564], ["epithelium", "ANATOMY_MODIFIER", 565, 575], ["pulmonary", "ANATOMY", 611, 620], ["immune response", "OBSERVATION", 621, 636], ["may be related to", "UNCERTAINTY", 725, 742]]], ["ACE2 appears to be the primary receptor for entry of SARS-CoV-2 into various epithelial tissues.", [["epithelial tissues", "ANATOMY", 77, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["epithelial tissues", "TISSUE", 77, 95], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["various", "ANATOMY_MODIFIER", 69, 76], ["epithelial tissues", "ANATOMY", 77, 95]]], ["An envelope anchored spike protein allows entry of coronaviruses into host cells by binding to a host receptor and fusing viral and host membranes.", [["cells", "ANATOMY", 75, 80], ["membranes", "ANATOMY", 137, 146], ["coronaviruses", "ORGANISM", 51, 64], ["host cells", "CELL", 70, 80], ["host membranes", "CELLULAR_COMPONENT", 132, 146], ["envelope anchored spike protein", "PROTEIN", 3, 34], ["host cells", "CELL_TYPE", 70, 80], ["An envelope anchored spike protein", "PROBLEM", 0, 34], ["coronaviruses into host cells", "PROBLEM", 51, 80], ["a host receptor", "TREATMENT", 95, 110], ["fusing viral and host membranes", "PROBLEM", 115, 146], ["host membranes", "OBSERVATION", 132, 146]]], ["2 Analysis of SARS-CoV, a betacoronavirus most similar to SARS-CoV-2 and responsible for Severe Acute Respiratory Syndrome (SARS), 3 defined a receptor-binding domain (RBD) of the SARS-CoV spike protein that specifically recognized ACE2.", [["SARS", "DISEASE", 58, 62], ["Acute Respiratory Syndrome", "DISEASE", 96, 122], ["SARS", "DISEASE", 124, 128], ["SARS-CoV", "ORGANISM", 14, 22], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 180, 188], ["ACE2", "GENE_OR_GENE_PRODUCT", 232, 236], ["receptor-binding domain", "PROTEIN", 143, 166], ["RBD", "PROTEIN", 168, 171], ["SARS-CoV spike protein", "PROTEIN", 180, 202], ["ACE2", "PROTEIN", 232, 236], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 58, 66], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 89, 129], ["SARS-CoV", "SPECIES", 180, 188], ["SARS", "PROBLEM", 14, 18], ["CoV", "PROBLEM", 19, 22], ["a betacoronavirus", "PROBLEM", 24, 41], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["Severe Acute Respiratory Syndrome", "PROBLEM", 89, 122], ["a receptor-binding domain (RBD", "PROBLEM", 141, 171], ["the SARS", "PROBLEM", 176, 184], ["CoV spike protein", "PROBLEM", 185, 202], ["responsible for", "UNCERTAINTY", 73, 88], ["Severe", "OBSERVATION_MODIFIER", 89, 95], ["Acute", "OBSERVATION_MODIFIER", 96, 101], ["Respiratory Syndrome", "OBSERVATION", 102, 122]]], ["4 Susceptibility to SARS appears to be primarily dependent on the affinity of the spike RBD to bind host ACE2 in target tissues in the initial viral attachment step, and differences in the affinity of the RBD for ACE2 may determine the zoonotic host and epidemiology of spread.", [["tissues", "ANATOMY", 120, 127], ["SARS", "DISEASE", 20, 24], ["RBD", "GENE_OR_GENE_PRODUCT", 88, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["tissues", "TISSUE", 120, 127], ["RBD", "GENE_OR_GENE_PRODUCT", 205, 208], ["ACE2", "GENE_OR_GENE_PRODUCT", 213, 217], ["RBD", "PROTEIN", 88, 91], ["ACE2", "PROTEIN", 105, 109], ["RBD", "PROTEIN", 205, 208], ["ACE2", "PROTEIN", 213, 217], ["SARS", "PROBLEM", 20, 24], ["the spike RBD", "PROBLEM", 78, 91], ["ACE2", "TEST", 213, 217], ["viral attachment", "OBSERVATION", 143, 159]]], ["5 Protein crystal structure analysis of the SARS-CoV RBD complexed with ACE2 demonstrated that this differential binding affinity resides in a critical receptor-binding motif of the spike receptor protein, and in particular the composition of amino acids 442, 472, 479, 480, and 487 determine affinity for human ACE2 as opposed to other hosts.", [["amino acids", "CHEMICAL", 243, 254], ["amino acids", "CHEMICAL", 243, 254], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["amino acids", "AMINO_ACID", 243, 254], ["442", "AMINO_ACID", 255, 258], ["human", "ORGANISM", 306, 311], ["ACE2", "GENE_OR_GENE_PRODUCT", 312, 316], ["SARS-CoV RBD", "PROTEIN", 44, 56], ["ACE2", "PROTEIN", 72, 76], ["receptor-binding motif", "PROTEIN", 152, 174], ["spike receptor protein", "PROTEIN", 182, 204], ["human ACE2", "PROTEIN", 306, 316], ["human", "SPECIES", 306, 311], ["SARS-CoV", "SPECIES", 44, 52], ["human", "SPECIES", 306, 311], ["Protein crystal structure analysis", "TEST", 2, 36], ["the SARS", "TEST", 40, 48], ["ACE2", "TEST", 72, 76], ["this differential binding affinity", "PROBLEM", 95, 129], ["the spike receptor protein", "TEST", 178, 204], ["amino acids", "TEST", 243, 254], ["human ACE2", "TREATMENT", 306, 316]]], ["5 Predicted protein structural analysis of these critical five residues in the SARS-CoV-2 analogous to SARS-CoV suggested an increased binding affinity to human ACE2 by SARS-CoV-2.", [["SARS", "DISEASE", 103, 107], ["SARS-CoV-2", "ORGANISM", 79, 89], ["SARS-CoV", "ORGANISM", 103, 111], ["human", "ORGANISM", 155, 160], ["ACE2", "GENE_OR_GENE_PRODUCT", 161, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["human ACE2", "PROTEIN", 155, 165], ["human", "SPECIES", 155, 160], ["SARS-CoV", "SPECIES", 103, 111], ["human", "SPECIES", 155, 160], ["protein structural analysis", "TEST", 12, 39], ["the SARS", "TEST", 75, 83], ["CoV", "TEST", 84, 87], ["SARS", "PROBLEM", 103, 107], ["an increased binding affinity", "PROBLEM", 122, 151]]], ["6 A synthetic SARS-CoV-2 RBD was found in vitro to bind and enter cells transfected only with a human ACE2 receptor and no other known coronavirus targets such as DPP4, the target of MERS-Co-V.", [["cells", "ANATOMY", 66, 71], ["SARS", "DISEASE", 14, 18], ["cells", "CELL", 66, 71], ["human", "ORGANISM", 96, 101], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 102, 115], ["coronavirus", "ORGANISM", 135, 146], ["DPP4", "GENE_OR_GENE_PRODUCT", 163, 167], ["RBD", "PROTEIN", 25, 28], ["human ACE2 receptor", "PROTEIN", 96, 115], ["DPP4", "PROTEIN", 163, 167], ["MERS", "PROTEIN", 183, 187], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["A synthetic SARS", "TEST", 2, 18], ["2 RBD", "PROBLEM", 23, 28], ["a human ACE2 receptor", "TREATMENT", 94, 115], ["other known coronavirus targets", "PROBLEM", 123, 154], ["DPP4", "TEST", 163, 167], ["coronavirus", "OBSERVATION", 135, 146]]], ["7 Therefore, it is rational to assume that like SARS-CoV, SARS-CoV-2 uses the ACE2 receptor on target tissues as its primary mechanism of entry.| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONRecent work with cryo electron microscopy of ACE2 bound to a spike protein fragment of SARS-CoV-2 8 suggests that the viral spike protein is a trimer, with one of the trimer RBD sites exposed to bind ACE2.", [["tissues", "ANATOMY", 102, 109], ["SARS", "DISEASE", 48, 52], ["SARS", "DISEASE", 58, 62], ["SARS-CoV", "ORGANISM", 48, 56], ["SARS-CoV-2", "ORGANISM", 58, 68], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 78, 91], ["tissues", "TISSUE", 102, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 238, 242], ["SARS-CoV-2 8", "GENE_OR_GENE_PRODUCT", 280, 292], ["ACE2", "GENE_OR_GENE_PRODUCT", 393, 397], ["ACE2 receptor", "PROTEIN", 78, 91], ["ACE2", "PROTEIN", 158, 162], ["ACE2", "PROTEIN", 238, 242], ["spike protein fragment", "PROTEIN", 254, 276], ["SARS-CoV-2 8", "DNA", 280, 292], ["viral spike protein", "PROTEIN", 311, 330], ["trimer RBD sites", "PROTEIN", 360, 376], ["ACE2", "PROTEIN", 393, 397], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["CoV", "PROBLEM", 53, 56], ["SARS", "PROBLEM", 58, 62], ["the ACE2 receptor", "TREATMENT", 74, 91], ["COVID", "TEST", 175, 180], ["cryo electron microscopy", "TEST", 210, 234], ["ACE2 bound", "PROBLEM", 238, 248], ["a spike protein fragment of SARS", "PROBLEM", 252, 284], ["CoV", "TEST", 285, 288], ["the viral spike protein", "PROBLEM", 307, 330], ["the trimer RBD sites", "PROBLEM", 356, 376], ["viral spike", "OBSERVATION", 311, 322], ["RBD", "OBSERVATION", 367, 370]]], ["Additional structure-function studies 9 also appear to indicate that the viral spike S protein of SARS-CoV-2 is highly glycosylated.| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONThe S protein is cleaved by proteases into two subunits (S1 and S2) and the S1 subunit is further divided into SA and SB domains, with the SB domain predicted to bind to human ACE2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["S1", "GENE_OR_GENE_PRODUCT", 238, 240], ["S2", "GENE_OR_GENE_PRODUCT", 245, 247], ["S1", "GENE_OR_GENE_PRODUCT", 257, 259], ["SA", "GENE_OR_GENE_PRODUCT", 292, 294], ["human", "ORGANISM", 351, 356], ["ACE2", "GENE_OR_GENE_PRODUCT", 357, 361], ["viral spike S protein", "PROTEIN", 73, 94], ["ACE2", "PROTEIN", 146, 150], ["S protein", "PROTEIN", 185, 194], ["proteases", "PROTEIN", 209, 218], ["S1", "PROTEIN", 238, 240], ["S2", "PROTEIN", 245, 247], ["S1 subunit", "PROTEIN", 257, 267], ["SA", "PROTEIN", 292, 294], ["SB domains", "PROTEIN", 299, 309], ["SB domain", "PROTEIN", 320, 329], ["human ACE2", "PROTEIN", 351, 361], ["human", "SPECIES", 351, 356], ["SARS-CoV", "SPECIES", 98, 106], ["human", "SPECIES", 351, 356], ["Additional structure-function studies", "TEST", 0, 37], ["the viral spike S protein", "TEST", 69, 94], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["COVID", "TEST", 163, 168], ["the S1 subunit", "TREATMENT", 253, 267], ["the SB domain", "PROBLEM", 316, 329], ["S2", "ANATOMY", 245, 247], ["S1", "ANATOMY", 257, 259]]], ["The S2 subunit is responsible for fusion of the virus-ACE2 complex with the cell membrane, and is highly glycosylated at evolutionarily conserved sites.", [["cell membrane", "ANATOMY", 76, 89], ["sites", "ANATOMY", 146, 151], ["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["cell membrane", "CELLULAR_COMPONENT", 76, 89], ["S2 subunit", "PROTEIN", 4, 14], ["virus-ACE2 complex", "PROTEIN", 48, 66], ["evolutionarily conserved sites", "DNA", 121, 151], ["fusion of the virus", "PROBLEM", 34, 53], ["the cell membrane", "TREATMENT", 72, 89], ["responsible for", "UNCERTAINTY", 18, 33], ["fusion", "OBSERVATION", 34, 40], ["virus", "OBSERVATION", 48, 53], ["cell membrane", "OBSERVATION", 76, 89]]], ["9 It is tempting to speculate that alterations in glycosylation of both the spike protein as well as ACE2 can modulate viral binding.", [["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["spike protein", "PROTEIN", 76, 89], ["ACE2", "PROTEIN", 101, 105], ["the spike protein", "PROBLEM", 72, 89], ["ACE2 can modulate viral binding", "PROBLEM", 101, 132]]], ["It is also tempting to speculate that alterations in the highly glycosylated and evolutionarily conserved viral fusion subunit could modulate S protein-ACE2 complex fusion with the cell membrane and potentially attenuate human to human transmission.| ROLE OF THE ACE2 RECEPTOR IN COVID-19 INFECTIONThe importance of ACE2 binding by SARS-CoV2 in COVID-19 is underscored by the observation that anosmia and dysgeusia have recently been observed in patients with COVID-19 10 and that ACE2 expression has recently been found to be high in the oropharynx and tongue.", [["cell membrane", "ANATOMY", 181, 194], ["oropharynx", "ANATOMY", 539, 549], ["tongue", "ANATOMY", 554, 560], ["SARS", "DISEASE", 332, 336], ["anosmia", "DISEASE", 393, 400], ["dysgeusia", "DISEASE", 405, 414], ["S protein", "GENE_OR_GENE_PRODUCT", 142, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["cell membrane", "CELLULAR_COMPONENT", 181, 194], ["human", "ORGANISM", 221, 226], ["human", "ORGANISM", 230, 235], ["ACE2", "GENE_OR_GENE_PRODUCT", 316, 320], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 332, 341], ["COVID-19", "GENE_OR_GENE_PRODUCT", 345, 353], ["patients", "ORGANISM", 446, 454], ["ACE2", "GENE_OR_GENE_PRODUCT", 481, 485], ["oropharynx", "ORGAN", 539, 549], ["tongue", "ORGAN", 554, 560], ["evolutionarily conserved viral fusion subunit", "PROTEIN", 81, 126], ["S protein", "PROTEIN", 142, 151], ["ACE2 complex", "PROTEIN", 152, 164], ["ACE2", "PROTEIN", 316, 320], ["COVID-19", "DNA", 345, 353], ["ACE2", "PROTEIN", 481, 485], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 230, 235], ["patients", "SPECIES", 446, 454], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 230, 235], ["alterations in the highly glycosylated", "PROBLEM", 38, 76], ["viral fusion subunit", "TREATMENT", 106, 126], ["ACE2 complex fusion", "TREATMENT", 152, 171], ["the cell membrane", "TREATMENT", 177, 194], ["INFECTION", "PROBLEM", 289, 298], ["ACE2 binding", "PROBLEM", 316, 328], ["anosmia", "PROBLEM", 393, 400], ["dysgeusia", "PROBLEM", 405, 414], ["COVID", "TEST", 460, 465], ["ACE2 expression", "PROBLEM", 481, 496], ["viral fusion", "OBSERVATION", 106, 118], ["cell membrane", "OBSERVATION", 181, 194], ["INFECTION", "OBSERVATION", 289, 298], ["high", "OBSERVATION", 527, 531], ["oropharynx", "ANATOMY", 539, 549], ["tongue", "ANATOMY", 554, 560]]], ["11| HYPERGLYCEMIA AND COVID-19 INFECTIONBinding of ACE2 by SARS-CoV-2 in COVID-19 also suggests that prolonged uncontrolled hyperglycemia, and not just a history of diabetes mellitus, may be important in the pathogenesis of the disease.| HYPERGLYCEMIA AND COVID-19 INFECTIONA known history of diabetes (DM) and ambient hyperglycemia were found to be independent risk factors for morbidity and mortality in SARS.", [["hyperglycemia", "DISEASE", 124, 137], ["diabetes mellitus", "DISEASE", 165, 182], ["diabetes", "DISEASE", 293, 301], ["DM", "DISEASE", 303, 305], ["hyperglycemia", "DISEASE", 319, 332], ["SARS", "DISEASE", 406, 410], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["COVID-19", "CELL", 73, 81], ["ACE2", "PROTEIN", 51, 55], ["HYPERGLYCEMIA", "TEST", 4, 17], ["COVID", "TEST", 22, 27], ["ACE2", "TEST", 51, 55], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["COVID", "TEST", 73, 78], ["prolonged uncontrolled hyperglycemia", "PROBLEM", 101, 137], ["diabetes mellitus", "PROBLEM", 165, 182], ["the disease", "PROBLEM", 224, 235], ["HYPERGLYCEMIA", "PROBLEM", 238, 251], ["COVID", "TEST", 256, 261], ["diabetes (DM)", "PROBLEM", 293, 306], ["ambient hyperglycemia", "PROBLEM", 311, 332], ["morbidity", "PROBLEM", 379, 388], ["mortality in SARS", "PROBLEM", 393, 410], ["prolonged", "OBSERVATION_MODIFIER", 101, 110], ["uncontrolled", "OBSERVATION_MODIFIER", 111, 123], ["hyperglycemia", "OBSERVATION", 124, 137], ["diabetes", "OBSERVATION", 165, 173], ["disease", "OBSERVATION", 228, 235], ["diabetes", "OBSERVATION", 293, 301]]], ["12 In a follow-up analysis of 135 patients, high fasting plasma glucose (FPG) was an independent predictor of SARS mortality.", [["plasma", "ANATOMY", 57, 63], ["glucose", "CHEMICAL", 64, 71], ["SARS", "DISEASE", 110, 114], ["glucose", "CHEMICAL", 64, 71], ["patients", "ORGANISM", 34, 42], ["plasma", "ORGANISM_SUBSTANCE", 57, 63], ["glucose", "SIMPLE_CHEMICAL", 64, 71], ["FPG", "SIMPLE_CHEMICAL", 73, 76], ["patients", "SPECIES", 34, 42], ["a follow-up analysis", "TEST", 6, 26], ["high fasting plasma glucose", "PROBLEM", 44, 71], ["FPG", "TEST", 73, 76], ["SARS mortality", "PROBLEM", 110, 124]]], ["13 Diabetes was found in 7.4% of a cohort of hospitalized COVID-19 patients and appeared to be a risk factor for severity of disease.", [["Diabetes", "DISEASE", 3, 11], ["COVID", "DISEASE", 58, 63], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Diabetes", "PROBLEM", 3, 11], ["disease", "PROBLEM", 125, 132], ["Diabetes", "OBSERVATION", 3, 11], ["disease", "OBSERVATION", 125, 132]]], ["14 A history of diabetes was associated with 22.5% of COVID-19 intensive care unit (ICU) admissions vs 5.9% of non-ICU admissions in one case series, 15 and another recent ICU case series reported 14 of 24 (58%) with a history of diabetes.", [["diabetes", "DISEASE", 16, 24], ["diabetes", "DISEASE", 230, 238], ["diabetes", "PROBLEM", 16, 24], ["diabetes", "PROBLEM", 230, 238], ["diabetes", "OBSERVATION", 16, 24], ["diabetes", "OBSERVATION", 230, 238]]], ["16 Mortality of COVID-19 in patients with diabetes was found to be 7.6% vs 0.9% in patients with no co-morbidities.", [["diabetes", "DISEASE", 42, 50], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 83, 91], ["COVID", "TEST", 16, 21], ["diabetes", "PROBLEM", 42, 50], ["co-morbidities", "PROBLEM", 100, 114]]], ["17 A possible explanation for a link between hyperglycemia and ACE2 levels in the severity of COVID-19 disease could be explained by several clinical observations in SARS and preclinical observations in the NOD diabetic mouse.", [["hyperglycemia", "DISEASE", 45, 58], ["COVID", "DISEASE", 94, 99], ["SARS", "DISEASE", 166, 170], ["diabetic", "DISEASE", 211, 219], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["COVID-19", "GENE_OR_GENE_PRODUCT", 94, 102], ["NOD", "ORGANISM", 207, 210], ["mouse", "ORGANISM", 220, 225], ["ACE2", "PROTEIN", 63, 67], ["mouse", "SPECIES", 220, 225], ["mouse", "SPECIES", 220, 225], ["a link between hyperglycemia", "PROBLEM", 30, 58], ["ACE2 levels", "TEST", 63, 74], ["COVID-19 disease", "PROBLEM", 94, 110], ["SARS", "PROBLEM", 166, 170], ["possible explanation for", "UNCERTAINTY", 5, 29], ["hyperglycemia", "OBSERVATION", 45, 58]]], ["As noted above, potential changes in glycosylation of the ACE2, as well as glycosylation of the viral spike protein, both possibly induced by uncontrolled hyperglycemia, may alter both the binding of the viral spike protein to ACE2 and the degree of the immune response to the virus.| HYPERGLYCEMIA AND COVID-19 INFECTIONIn a subset of 39 patients who had no prior diabetes, received no steroid treatment during hospitalization, and who survived SARS, FPG levels during hospitalization were found to decrease before discharge.", [["hyperglycemia", "DISEASE", 155, 168], ["diabetes", "DISEASE", 365, 373], ["steroid", "CHEMICAL", 387, 394], ["SARS", "DISEASE", 446, 450], ["steroid", "CHEMICAL", 387, 394], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 227, 231], ["patients", "ORGANISM", 339, 347], ["FPG", "SIMPLE_CHEMICAL", 452, 455], ["ACE2", "PROTEIN", 58, 62], ["viral spike protein", "PROTEIN", 96, 115], ["viral spike protein", "PROTEIN", 204, 223], ["ACE2", "PROTEIN", 227, 231], ["patients", "SPECIES", 339, 347], ["glycosylation of the ACE2", "TREATMENT", 37, 62], ["glycosylation", "TREATMENT", 75, 88], ["the viral spike protein", "PROBLEM", 92, 115], ["uncontrolled hyperglycemia", "PROBLEM", 142, 168], ["the viral spike protein", "PROBLEM", 200, 223], ["ACE2", "TEST", 227, 231], ["the virus", "PROBLEM", 273, 282], ["HYPERGLYCEMIA", "PROBLEM", 285, 298], ["COVID", "TEST", 303, 308], ["prior diabetes", "PROBLEM", 359, 373], ["steroid treatment", "TREATMENT", 387, 404], ["FPG levels", "TEST", 452, 462], ["uncontrolled", "OBSERVATION_MODIFIER", 142, 154], ["hyperglycemia", "OBSERVATION", 155, 168], ["viral spike", "OBSERVATION", 204, 215], ["immune response", "OBSERVATION", 254, 269], ["no", "UNCERTAINTY", 356, 358], ["diabetes", "OBSERVATION", 365, 373]]], ["13 Twenty of these 39 (51%) patients had diabetes during hospitalization, 13 suggested that it could cause harm.", [["diabetes", "DISEASE", 41, 49], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["diabetes", "PROBLEM", 41, 49]]], ["19 It is interesting to note, that as this article was going to press, that another group has expressed a similar hypothesis.", [["a similar hypothesis", "PROBLEM", 104, 124], ["similar", "OBSERVATION_MODIFIER", 106, 113], ["hypothesis", "OBSERVATION", 114, 124]]], ["20 Potentially high and aberrantly glycosylated ACE2 in the lung, nasal airways, tongue, and oropharynx in uncontrolled hyperglycemia could also serve as increased SARS-CoV-2 viral binding sites, thus leading to a higher propensity to COVID-19 infection and a higher disease severity.| HYPERGLYCEMIA AND COVID-19 INFECTIONInterestingly, high ACE2 has a protective effect in various organs.", [["lung", "ANATOMY", 60, 64], ["nasal airways", "ANATOMY", 66, 79], ["tongue", "ANATOMY", 81, 87], ["oropharynx", "ANATOMY", 93, 103], ["organs", "ANATOMY", 382, 388], ["hyperglycemia", "DISEASE", 120, 133], ["infection", "DISEASE", 244, 253], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["lung", "ORGAN", 60, 64], ["nasal airways", "MULTI-TISSUE_STRUCTURE", 66, 79], ["tongue", "ORGAN", 81, 87], ["oropharynx", "ORGAN", 93, 103], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["COVID-19", "GENE_OR_GENE_PRODUCT", 235, 243], ["ACE2", "GENE_OR_GENE_PRODUCT", 342, 346], ["organs", "ORGAN", 382, 388], ["ACE2", "PROTEIN", 48, 52], ["SARS-CoV-2 viral binding sites", "DNA", 164, 194], ["ACE2", "PROTEIN", 342, 346], ["COVID-19", "SPECIES", 235, 243], ["aberrantly glycosylated ACE2 in the lung, nasal airways, tongue, and oropharynx in uncontrolled hyperglycemia", "PROBLEM", 24, 133], ["increased SARS", "PROBLEM", 154, 168], ["CoV", "PROBLEM", 169, 172], ["2 viral binding sites", "PROBLEM", 173, 194], ["COVID", "TEST", 235, 240], ["19 infection", "PROBLEM", 241, 253], ["a higher disease severity", "PROBLEM", 258, 283], ["HYPERGLYCEMIA", "PROBLEM", 286, 299], ["COVID", "TEST", 304, 309], ["INFECTIONInterestingly", "PROBLEM", 313, 335], ["high ACE2", "PROBLEM", 337, 346], ["high", "OBSERVATION_MODIFIER", 15, 19], ["glycosylated ACE2", "OBSERVATION", 35, 52], ["lung", "ANATOMY", 60, 64], ["nasal airways", "ANATOMY", 66, 79], ["tongue", "ANATOMY", 81, 87], ["oropharynx", "ANATOMY", 93, 103], ["uncontrolled", "OBSERVATION_MODIFIER", 107, 119], ["hyperglycemia", "OBSERVATION", 120, 133], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["SARS", "OBSERVATION", 164, 168], ["infection", "OBSERVATION", 244, 253], ["higher", "OBSERVATION_MODIFIER", 260, 266], ["disease", "OBSERVATION", 267, 274], ["19 INFECTIONInterestingly", "OBSERVATION_MODIFIER", 310, 335], ["protective effect", "OBSERVATION_MODIFIER", 353, 370]]], ["21 ACE2 gene expression is increased by estrogen in a mouse model 22 a potential protective factor for SARS-CoV-2 infection and pathogenicity, as men are more likely than women to both acquire COVID-19 and have more severe disease.", [["estrogen", "CHEMICAL", 40, 48], ["infection", "DISEASE", 114, 123], ["estrogen", "CHEMICAL", 40, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 3, 7], ["estrogen", "SIMPLE_CHEMICAL", 40, 48], ["mouse", "ORGANISM", 54, 59], ["SARS-CoV-2", "ORGANISM", 103, 113], ["men", "ORGANISM", 146, 149], ["women", "ORGANISM", 171, 176], ["ACE2", "PROTEIN", 3, 7], ["mouse", "SPECIES", 54, 59], ["men", "SPECIES", 146, 149], ["women", "SPECIES", 171, 176], ["mouse", "SPECIES", 54, 59], ["SARS-CoV-2", "SPECIES", 103, 113], ["ACE2 gene expression", "TREATMENT", 3, 23], ["SARS", "PROBLEM", 103, 107], ["CoV", "PROBLEM", 108, 111], ["2 infection", "PROBLEM", 112, 123], ["pathogenicity", "PROBLEM", 128, 141], ["COVID", "TEST", 193, 198], ["more severe disease", "PROBLEM", 211, 230], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["infection", "OBSERVATION", 114, 123], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["disease", "OBSERVATION", 223, 230]]], ["Recent survey studies found that ACE2 gene expression was higher in tissues of women and in younger adults, an inverse correlation to disease severity.", [["tissues", "ANATOMY", 68, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["tissues", "TISSUE", 68, 75], ["women", "ORGANISM", 79, 84], ["ACE2", "PROTEIN", 33, 37], ["women", "SPECIES", 79, 84], ["Recent survey studies", "TEST", 0, 21], ["ACE2 gene expression", "PROBLEM", 33, 53], ["disease severity", "PROBLEM", 134, 150], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["23 A possible explanation for this discrepancy is that gene expression experiments cannot measure posttranslational modifications such as protein glycosylation.", [["this discrepancy", "PROBLEM", 30, 46], ["gene expression experiments", "PROBLEM", 55, 82], ["posttranslational modifications", "TREATMENT", 98, 129], ["protein glycosylation", "TREATMENT", 138, 159], ["possible explanation for", "UNCERTAINTY", 5, 29]]], ["In the NOD diabetic mouse model, ACE2 activity in the lung did not rise and then fall with insulin administration, but the amount of ACE2 protein apparently did.", [["lung", "ANATOMY", 54, 58], ["diabetic", "DISEASE", 11, 19], ["mouse", "ORGANISM", 20, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["lung", "ORGAN", 54, 58], ["insulin", "GENE_OR_GENE_PRODUCT", 91, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["ACE2", "PROTEIN", 33, 37], ["ACE2", "PROTEIN", 133, 137], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["ACE2 activity in the lung", "PROBLEM", 33, 58], ["insulin administration", "TREATMENT", 91, 113], ["ACE2 protein", "TEST", 133, 145], ["diabetic mouse model", "OBSERVATION", 11, 31], ["lung", "ANATOMY", 54, 58]]], ["18 This is consistent with a rise in glycosylated ACE2, as opposed to total ACE2, since antibody binding to proteins as measured by Western blot analysis could be affected by glycosylation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["glycosylated ACE2", "PROTEIN", 37, 54], ["ACE2", "PROTEIN", 76, 80], ["a rise in glycosylated ACE2", "PROBLEM", 27, 54], ["total ACE2", "TEST", 70, 80], ["antibody binding", "PROBLEM", 88, 104], ["blot analysis", "TEST", 140, 153], ["consistent with", "UNCERTAINTY", 11, 26], ["rise", "OBSERVATION_MODIFIER", 29, 33], ["glycosylated ACE2", "OBSERVATION", 37, 54]]], ["24 Therefore, it is likely that it is the amount of glycosylated ACE2 receptor, and not simply the amount of ACE2 alone, that is responsible for virus binding and fusion.| HYPERGLYCEMIA AND COVID-19 INFECTIONIf true, this argues for better glycemic control in patients with prediabetes and diabetes as a potential mechanism to slow COVID-19 spread and reduce the severity of symptoms.", [["prediabetes", "DISEASE", 274, 285], ["diabetes", "DISEASE", 290, 298], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 65, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["patients", "ORGANISM", 260, 268], ["glycosylated ACE2 receptor", "PROTEIN", 52, 78], ["ACE2", "PROTEIN", 109, 113], ["patients", "SPECIES", 260, 268], ["glycosylated ACE2 receptor", "TREATMENT", 52, 78], ["virus binding", "PROBLEM", 145, 158], ["HYPERGLYCEMIA", "PROBLEM", 172, 185], ["COVID", "TEST", 190, 195], ["INFECTIONIf true", "PROBLEM", 199, 215], ["prediabetes", "PROBLEM", 274, 285], ["diabetes", "PROBLEM", 290, 298], ["slow COVID", "PROBLEM", 327, 337], ["the severity of symptoms", "PROBLEM", 359, 383], ["is likely", "UNCERTAINTY", 17, 26], ["responsible for", "UNCERTAINTY", 129, 144], ["19 INFECTIONIf", "OBSERVATION_MODIFIER", 196, 210], ["true", "OBSERVATION_MODIFIER", 211, 215]]], ["Additionally, since 3.8% of the American population without a history of diabetes or prediabetes has a hemoglobin A1c over 6.1% in random sampling, 25 This appears to be coincident with a peak in viral load as measured in nasopharyngeal swabs at day 10 after symptom onset in SARS.", [["nasopharyngeal swabs", "ANATOMY", 222, 242], ["diabetes", "DISEASE", 73, 81], ["prediabetes", "DISEASE", 85, 96], ["SARS", "DISEASE", 276, 280], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 103, 113], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 222, 242], ["hemoglobin", "PROTEIN", 103, 113], ["diabetes", "PROBLEM", 73, 81], ["prediabetes", "PROBLEM", 85, 96], ["a hemoglobin A1c", "TEST", 101, 117], ["random sampling", "TEST", 131, 146], ["a peak in viral load", "PROBLEM", 186, 206], ["nasopharyngeal swabs", "TEST", 222, 242], ["SARS", "PROBLEM", 276, 280], ["diabetes", "OBSERVATION", 73, 81], ["viral load", "OBSERVATION", 196, 206], ["nasopharyngeal swabs", "ANATOMY", 222, 242]]], ["26 The timing of the ARDS in SARS also corresponded to the timing of immunoglobulin G (IgG) seroconversion.", [["ARDS", "DISEASE", 21, 25], ["SARS", "DISEASE", 29, 33], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 69, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["immunoglobulin G", "PROTEIN", 69, 85], ["IgG", "PROTEIN", 87, 90], ["the ARDS", "PROBLEM", 17, 25], ["SARS", "PROBLEM", 29, 33], ["immunoglobulin G (IgG) seroconversion", "TREATMENT", 69, 106], ["ARDS", "OBSERVATION", 21, 25]]], ["26 Additionally, the neutralizing antibody (Nab) response to the SARS-CoV spike protein in patients who died of SARS occurred earlier in the course of the disease (14.7 days after symptom onset) vs those who survived (20 days), and the Nab antibody titer was higher in those who died of SARS than in those survived.", [["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 287, 291], ["Nab", "GENE_OR_GENE_PRODUCT", 44, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["patients", "ORGANISM", 91, 99], ["Nab antibody", "GENE_OR_GENE_PRODUCT", 236, 248], ["neutralizing antibody", "PROTEIN", 21, 42], ["Nab", "PROTEIN", 44, 47], ["SARS-CoV spike protein", "PROTEIN", 65, 87], ["Nab antibody", "PROTEIN", 236, 248], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 65, 73], ["the neutralizing antibody", "TEST", 17, 42], ["the SARS", "PROBLEM", 61, 69], ["CoV spike protein", "PROBLEM", 70, 87], ["SARS", "PROBLEM", 112, 116], ["the disease", "PROBLEM", 151, 162], ["the Nab antibody titer", "TEST", 232, 254], ["SARS", "PROBLEM", 287, 291]]], ["27 Notably, viral load in COVID-19 in severe cases appears to remain high 10 days after symptom onset 28 and it is tempting to hypothesize that a similar mechanism applies to SARS-CoV-2.", [["COVID-19", "CHEMICAL", 26, 34], ["SARS", "DISEASE", 175, 179], ["SARS-CoV-2", "ORGANISM", 175, 185], ["SARS-CoV", "SPECIES", 175, 183], ["viral load", "TEST", 12, 22], ["COVID", "TEST", 26, 31], ["severe cases", "PROBLEM", 38, 50], ["symptom onset", "PROBLEM", 88, 101], ["viral load", "OBSERVATION", 12, 22]]], ["The acute onset of lung inflammation in SARS resulting in ARDS appears to be tightly associated with monocyte/macrophage polarization and function.", [["lung", "ANATOMY", 19, 23], ["monocyte", "ANATOMY", 101, 109], ["macrophage", "ANATOMY", 110, 120], ["lung inflammation", "DISEASE", 19, 36], ["SARS", "DISEASE", 40, 44], ["ARDS", "DISEASE", 58, 62], ["lung", "ORGAN", 19, 23], ["monocyte", "CELL", 101, 109], ["macrophage", "CELL", 110, 120], ["lung inflammation", "PROBLEM", 19, 36], ["SARS", "PROBLEM", 40, 44], ["ARDS", "PROBLEM", 58, 62], ["monocyte/macrophage polarization", "TREATMENT", 101, 133], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["onset", "OBSERVATION_MODIFIER", 10, 15], ["lung", "ANATOMY", 19, 23], ["inflammation", "OBSERVATION", 24, 36], ["ARDS", "OBSERVATION", 58, 62], ["macrophage polarization", "OBSERVATION", 110, 133]]], ["31 During acute infection, macrophages display a classically activated inflammatory M1 phenotype and express cytokines such as interleukin-6 (IL-6).", [["macrophages", "ANATOMY", 27, 38], ["acute infection", "DISEASE", 10, 25], ["macrophages", "CELL", 27, 38], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 127, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 142, 146], ["macrophages", "CELL_TYPE", 27, 38], ["cytokines", "PROTEIN", 109, 118], ["interleukin-6", "PROTEIN", 127, 140], ["IL", "PROTEIN", 142, 144], ["acute infection", "PROBLEM", 10, 25], ["macrophages", "PROBLEM", 27, 38], ["a classically activated inflammatory M1 phenotype", "PROBLEM", 47, 96], ["interleukin", "TEST", 127, 138], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25], ["macrophages", "OBSERVATION", 27, 38], ["inflammatory M1 phenotype", "OBSERVATION", 71, 96]]], ["High IL-6 levels were associated BRUFSKY | 3 with increased mortality in a series of 191 hospitalized patients with It is tempting to consider that the same mechanism acts in COVID-19 as in SARS, where an overactive macrophage M1 inflammatory response, as neutralizing antibodies to the SARS-CoV-2 spike protein form at day 7 to 10, results in ARDS in susceptible patients.", [["macrophage", "ANATOMY", 216, 226], ["SARS", "DISEASE", 190, 194], ["ARDS", "DISEASE", 344, 348], ["IL-6", "GENE_OR_GENE_PRODUCT", 5, 9], ["BRUFSKY | 3", "GENE_OR_GENE_PRODUCT", 33, 44], ["patients", "ORGANISM", 102, 110], ["macrophage M1", "CELL", 216, 229], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 287, 297], ["patients", "ORGANISM", 364, 372], ["IL-6", "PROTEIN", 5, 9], ["neutralizing antibodies", "PROTEIN", 256, 279], ["SARS-CoV-2 spike protein", "PROTEIN", 287, 311], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 364, 372], ["increased mortality", "PROBLEM", 50, 69], ["COVID", "TEST", 175, 180], ["SARS", "PROBLEM", 190, 194], ["an overactive macrophage M1 inflammatory response", "PROBLEM", 202, 251], ["neutralizing antibodies", "TEST", 256, 279], ["the SARS", "TEST", 283, 291], ["CoV", "TEST", 292, 295], ["spike protein", "TEST", 298, 311], ["ARDS", "PROBLEM", 344, 348], ["overactive", "OBSERVATION_MODIFIER", 205, 215], ["macrophage M1", "OBSERVATION", 216, 229], ["ARDS", "OBSERVATION", 344, 348]]], ["It is also allows consideration of agents which may interfere with this overly brisk macrophage inflammatory response and perhaps influence the course of the disease, in particular those that blunt but do not completely abrogate M2 to M1 balance in macrophage polarization, as well as viral load, which in SARS appears to be temporally related to the onset of ARDS.| HYPERGLYCEMIA AND COVID-19 INFECTIONIt is of interest that in a mouse model of asthma, macrophage M2 polarization is increased by estrogen.", [["macrophage", "ANATOMY", 85, 95], ["macrophage", "ANATOMY", 249, 259], ["macrophage", "ANATOMY", 454, 464], ["SARS", "DISEASE", 306, 310], ["ARDS", "DISEASE", 360, 364], ["asthma", "DISEASE", 446, 452], ["estrogen", "CHEMICAL", 497, 505], ["estrogen", "CHEMICAL", 497, 505], ["macrophage", "CELL", 85, 95], ["M2", "GENE_OR_GENE_PRODUCT", 229, 231], ["M1", "CELL", 235, 237], ["macrophage", "CELL", 249, 259], ["mouse", "ORGANISM", 431, 436], ["macrophage", "CELL", 454, 464], ["M2", "GENE_OR_GENE_PRODUCT", 465, 467], ["estrogen", "SIMPLE_CHEMICAL", 497, 505], ["mouse", "SPECIES", 431, 436], ["mouse", "SPECIES", 431, 436], ["agents", "TREATMENT", 35, 41], ["this overly brisk macrophage inflammatory response", "PROBLEM", 67, 117], ["the disease", "PROBLEM", 154, 165], ["macrophage polarization", "TEST", 249, 272], ["viral load", "PROBLEM", 285, 295], ["SARS", "PROBLEM", 306, 310], ["ARDS", "PROBLEM", 360, 364], ["HYPERGLYCEMIA", "PROBLEM", 367, 380], ["COVID", "TEST", 385, 390], ["asthma", "PROBLEM", 446, 452], ["macrophage M2 polarization", "TREATMENT", 454, 480], ["macrophage", "OBSERVATION_MODIFIER", 85, 95], ["inflammatory", "OBSERVATION", 96, 108], ["disease", "OBSERVATION", 158, 165], ["macrophage polarization", "OBSERVATION", 249, 272], ["viral load", "OBSERVATION", 285, 295], ["ARDS", "OBSERVATION", 360, 364], ["19 INFECTIONIt", "OBSERVATION_MODIFIER", 391, 405], ["asthma", "OBSERVATION", 446, 452], ["macrophage M2", "OBSERVATION", 454, 467], ["increased", "OBSERVATION_MODIFIER", 484, 493]]], ["32 Additionally, estrogen also accelerates acquisition of an M2 phenotype in a monocyte cell culture model.", [["monocyte cell culture", "ANATOMY", 79, 100], ["estrogen", "CHEMICAL", 17, 25], ["estrogen", "CHEMICAL", 17, 25], ["estrogen", "SIMPLE_CHEMICAL", 17, 25], ["M2", "GENE_OR_GENE_PRODUCT", 61, 63], ["monocyte cell", "CELL", 79, 92], ["monocyte cell culture model", "CELL_LINE", 79, 106], ["an M2 phenotype", "PROBLEM", 58, 73], ["a monocyte cell culture model", "TEST", 77, 106], ["monocyte cell", "OBSERVATION", 79, 92]]], ["33 in vitro at concentrations achievable in human lung tissue.", [["lung tissue", "ANATOMY", 50, 61], ["human", "ORGANISM", 44, 49], ["lung tissue", "TISSUE", 50, 61], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["vitro at concentrations", "TREATMENT", 6, 29], ["human", "ANATOMY_MODIFIER", 44, 49], ["lung", "ANATOMY", 50, 54], ["tissue", "OBSERVATION", 55, 61]]], ["35 Chloroquine, a related compound, inhibits SARS-CoV replication and spread in cell culture, possibly through reducing glycosylation of the ACE2 receptor.", [["cell culture", "ANATOMY", 80, 92], ["Chloroquine", "CHEMICAL", 3, 14], ["Chloroquine", "CHEMICAL", 3, 14], ["Chloroquine", "SIMPLE_CHEMICAL", 3, 14], ["SARS-CoV", "ORGANISM", 45, 53], ["cell culture", "CELL", 80, 92], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 141, 154], ["ACE2 receptor", "PROTEIN", 141, 154], ["SARS-CoV", "SPECIES", 45, 53], ["Chloroquine", "TREATMENT", 3, 14], ["a related compound", "PROBLEM", 16, 34], ["SARS", "PROBLEM", 45, 49], ["CoV replication", "TREATMENT", 50, 65], ["spread in cell culture", "TEST", 70, 92], ["the ACE2 receptor", "TREATMENT", 137, 154]]], ["36 Interestingly, computer simulations suggest that hydroxychloroquine and chloroquine are predicted to bind to the active site of the enzyme UDP-N-acetylglucosamine 2-epimerase, which catalyzes the rate determining step in the sialic acid biosynthesis pathway, 37 and thus there is a rational basis to assume hydroxychloroquine can interfere in terminal glycosylation of proteins in the Golgi apparatus.| HYPERGLYCEMIA AND COVID-19 INFECTIONIn a small unrandomized clinical cohort of 80 patients the combination of hydroxychloroquine and azithromycin has been shown to rapidly reduce viral load in COVID-19 patients and ameliorate clinical symptoms in the majority of patients.", [["Golgi apparatus", "ANATOMY", 388, 403], ["hydroxychloroquine", "CHEMICAL", 52, 70], ["chloroquine", "CHEMICAL", 75, 86], ["UDP-N-acetylglucosamine", "CHEMICAL", 142, 165], ["sialic acid", "CHEMICAL", 228, 239], ["hydroxychloroquine", "CHEMICAL", 310, 328], ["hydroxychloroquine", "CHEMICAL", 516, 534], ["azithromycin", "CHEMICAL", 539, 551], ["hydroxychloroquine", "CHEMICAL", 52, 70], ["chloroquine", "CHEMICAL", 75, 86], ["UDP", "CHEMICAL", 142, 145], ["N-acetylglucosamine", "CHEMICAL", 146, 165], ["sialic acid", "CHEMICAL", 228, 239], ["hydroxychloroquine", "CHEMICAL", 310, 328], ["hydroxychloroquine", "CHEMICAL", 516, 534], ["azithromycin", "CHEMICAL", 539, 551], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 52, 70], ["chloroquine", "SIMPLE_CHEMICAL", 75, 86], ["UDP-N-acetylglucosamine 2-epimerase", "GENE_OR_GENE_PRODUCT", 142, 177], ["sialic acid", "SIMPLE_CHEMICAL", 228, 239], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 310, 328], ["Golgi apparatus", "CELLULAR_COMPONENT", 388, 403], ["patients", "ORGANISM", 488, 496], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 516, 534], ["azithromycin", "SIMPLE_CHEMICAL", 539, 551], ["patients", "ORGANISM", 608, 616], ["patients", "ORGANISM", 669, 677], ["enzyme UDP-N-acetylglucosamine 2-epimerase", "PROTEIN", 135, 177], ["patients", "SPECIES", 488, 496], ["patients", "SPECIES", 608, 616], ["patients", "SPECIES", 669, 677], ["hydroxychloroquine", "TREATMENT", 52, 70], ["chloroquine", "TREATMENT", 75, 86], ["the enzyme UDP", "TEST", 131, 145], ["N-acetylglucosamine", "TREATMENT", 146, 165], ["the sialic acid biosynthesis pathway", "TEST", 224, 260], ["hydroxychloroquine", "TREATMENT", 310, 328], ["terminal glycosylation of proteins", "PROBLEM", 346, 380], ["HYPERGLYCEMIA", "PROBLEM", 406, 419], ["COVID", "TEST", 424, 429], ["hydroxychloroquine", "TREATMENT", 516, 534], ["azithromycin", "TREATMENT", 539, 551], ["viral load in COVID", "PROBLEM", 585, 604], ["clinical symptoms", "PROBLEM", 632, 649], ["19 INFECTIONIn", "OBSERVATION_MODIFIER", 430, 444], ["small", "OBSERVATION_MODIFIER", 447, 452]]], ["38 In another small randomized Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate, 40 and thus can serve to reduce hyperglycemia, a possible COVID-19 risk factor for disease severity.| HYPERGLYCEMIA AND COVID-19 INFECTIONWhile studies are mixed on this topic, and the balance of M1 to M2 macrophage polarization may differ depending on the local microenvironment, hydroxychloroquine has been shown in at least one study to block the polarization of macrophages to an M1 inflammatory subtype, 41| CONCLUSION AND SUMMARYWhile we await larger randomized studies and more analysis of patient subtypes to determine who, if anyone, will benefit from hydroxychloroquine, in the context of this theoretical framework for COVID-19 infection the results to date are supportive, although much caution should be used in interpretation of these early small clinical trials.| CONCLUSION AND SUMMARYRegardless of the results of larger clinical trials of hydroxychloroquine in COVID-19, it is hoped that the above analysis can provide a testable theoretical framework to allow for advances in our understanding and control of this deadly viral epidemic.", [["oral", "ANATOMY", 69, 73], ["macrophage", "ANATOMY", 455, 465], ["macrophages", "ANATOMY", 616, 627], ["Hydroxychloroquine", "CHEMICAL", 31, 49], ["diabetes", "DISEASE", 111, 119], ["hydroxychloroquine", "CHEMICAL", 127, 145], ["rheumatologic diseases", "DISEASE", 150, 172], ["methotrexate", "CHEMICAL", 236, 248], ["hyperglycemia", "DISEASE", 282, 295], ["hydroxychloroquine", "CHEMICAL", 531, 549], ["hydroxychloroquine", "CHEMICAL", 811, 829], ["infection", "DISEASE", 889, 898], ["hydroxychloroquine", "CHEMICAL", 1106, 1124], ["Hydroxychloroquine", "CHEMICAL", 31, 49], ["hydroxychloroquine", "CHEMICAL", 127, 145], ["methotrexate", "CHEMICAL", 236, 248], ["hydroxychloroquine", "CHEMICAL", 531, 549], ["hydroxychloroquine", "CHEMICAL", 811, 829], ["hydroxychloroquine", "CHEMICAL", 1106, 1124], ["COVID-19", "CHEMICAL", 1128, 1136], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["patients", "ORGANISM", 97, 105], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 127, 145], ["hemoglobin A1c", "GENE_OR_GENE_PRODUCT", 204, 218], ["methotrexate", "SIMPLE_CHEMICAL", 236, 248], ["M1", "CELL", 446, 448], ["M2 macrophage", "CELL", 452, 465], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 531, 549], ["macrophages", "CELL", 616, 627], ["patient", "ORGANISM", 747, 754], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 811, 829], ["COVID-19", "ORGANISM", 880, 888], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 1106, 1124], ["hemoglobin", "PROTEIN", 204, 214], ["macrophages", "CELL_TYPE", 616, 627], ["patients", "SPECIES", 97, 105], ["patient", "SPECIES", 747, 754], ["another small randomized Hydroxychloroquine", "TREATMENT", 6, 49], ["an oral hypoglycemic agent", "TREATMENT", 66, 92], ["diabetes", "PROBLEM", 111, 119], ["hydroxychloroquine", "TREATMENT", 127, 145], ["rheumatologic diseases", "PROBLEM", 150, 172], ["a significant reduction in hemoglobin A1c", "PROBLEM", 177, 218], ["methotrexate", "TREATMENT", 236, 248], ["hyperglycemia", "PROBLEM", 282, 295], ["COVID", "TEST", 308, 313], ["disease severity", "PROBLEM", 333, 349], ["HYPERGLYCEMIA", "PROBLEM", 352, 365], ["COVID", "TEST", 370, 375], ["INFECTIONWhile studies", "TEST", 379, 401], ["hydroxychloroquine", "TREATMENT", 531, 549], ["larger randomized studies", "TEST", 700, 725], ["hydroxychloroquine", "TREATMENT", 811, 829], ["COVID-19 infection", "PROBLEM", 880, 898], ["hydroxychloroquine in COVID", "TREATMENT", 1106, 1133], ["the above analysis", "TEST", 1155, 1173], ["this deadly viral epidemic", "PROBLEM", 1277, 1303], ["small", "OBSERVATION_MODIFIER", 14, 19], ["significant", "OBSERVATION_MODIFIER", 179, 190], ["reduction", "OBSERVATION_MODIFIER", 191, 200], ["hemoglobin A1c", "OBSERVATION", 204, 218], ["macrophages", "OBSERVATION", 616, 627], ["M1", "ANATOMY", 634, 636]]]], "af7dfbc201a1170bda12125baa1ab67cd040bf5e": [["A c c e p t e d M a n u s c r i p t Dear Editor, With interest, we read the study by Sarah et al. who reported the first mildly Ill, nonhospitalized case of COVID-19 in the United States [1] .", [["a n u s", "TEST", 18, 25], ["the study", "TEST", 72, 81], ["mildly Ill", "PROBLEM", 121, 131], ["COVID", "TEST", 157, 162]]], ["The authors conducted rigorous public health surveys, contact tracking and serial SARSCoV-2 testing.", [["serial SARSCoV-2 testing", "TEST", 75, 99]]], ["In their research, despite specimens testing positive 18 days after diagnosis, no SARS-CoV-2 transmission occurred among 10 high-risk contacts of this patient, including 1 intimate contact.", [["specimens", "ANATOMY", 27, 36], ["SARS", "DISEASE", 82, 86], ["specimens", "CANCER", 27, 36], ["SARS-CoV-2", "ORGANISM", 82, 92], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["SARS-CoV", "SPECIES", 82, 90], ["specimens testing", "TEST", 27, 44], ["SARS", "PROBLEM", 82, 86]]], ["This study provided important insights for the spread of COVID-19.", [["COVID-19", "CHEMICAL", 57, 65], ["COVID-19", "DNA", 57, 65], ["This study", "TEST", 0, 10], ["COVID", "TEST", 57, 62]]], ["However, they promoted the possibility that mild cases can be released from isolation based on symptom resolution.", [["mild cases", "PROBLEM", 44, 54], ["symptom resolution", "TEST", 95, 113], ["mild", "OBSERVATION_MODIFIER", 44, 48]]]], "PMC3706912": [["No effective pharmacologic therapies currently exist for acute lung injury (ALI) or its more severe form, the acute respiratory distress syndrome (ARDS).", [["lung", "ANATOMY", 63, 67], ["respiratory", "ANATOMY", 116, 127], ["acute lung injury", "DISEASE", 57, 74], ["ALI", "DISEASE", 76, 79], ["acute respiratory distress syndrome", "DISEASE", 110, 145], ["ARDS", "DISEASE", 147, 151], ["lung", "ORGAN", 63, 67], ["effective pharmacologic therapies", "TREATMENT", 3, 36], ["acute lung injury", "PROBLEM", 57, 74], ["ALI", "PROBLEM", 76, 79], ["the acute respiratory distress syndrome", "PROBLEM", 106, 145], ["ARDS", "PROBLEM", 147, 151], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["pharmacologic", "OBSERVATION", 13, 26], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["lung", "ANATOMY", 63, 67], ["injury", "OBSERVATION", 68, 74], ["more severe", "OBSERVATION_MODIFIER", 88, 99], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory distress syndrome", "OBSERVATION", 116, 145]]], ["The only treatment positively affecting mortality in ARDS is low-tidal volume ventilation, but even when this is used mortality remains high, at approximately 40% [1].", [["ARDS", "DISEASE", 53, 57], ["ARDS", "PROBLEM", 53, 57], ["low-tidal volume ventilation", "TREATMENT", 61, 89], ["ARDS", "OBSERVATION", 53, 57], ["tidal volume", "OBSERVATION", 65, 77]]], ["Thus, there is an urgent need for effective therapies for ALI/ARDS.", [["ALI", "DISEASE", 58, 61], ["ARDS", "DISEASE", 62, 66], ["effective therapies", "TREATMENT", 34, 53], ["ALI", "PROBLEM", 58, 61], ["ARDS", "PROBLEM", 62, 66], ["ARDS", "OBSERVATION", 62, 66]]], ["Mesenchymal stem cells (MSCs) are progenitor cells having self-renewal and multi-lineage differentiation capabilities along with anti-inflammatory and immuno-suppressive activities.", [["Mesenchymal stem cells", "ANATOMY", 0, 22], ["MSCs", "ANATOMY", 24, 28], ["progenitor cells", "ANATOMY", 34, 50], ["Mesenchymal stem cells", "CELL", 0, 22], ["MSCs", "CELL", 24, 28], ["progenitor cells", "CELL", 34, 50], ["Mesenchymal stem cells", "CELL_TYPE", 0, 22], ["MSCs", "CELL_TYPE", 24, 28], ["progenitor cells", "CELL_TYPE", 34, 50], ["Mesenchymal stem cells", "PROBLEM", 0, 22], ["progenitor cells", "PROBLEM", 34, 50], ["self-renewal", "TREATMENT", 58, 70], ["anti-inflammatory and immuno-suppressive activities", "TREATMENT", 129, 180], ["stem cells", "OBSERVATION", 12, 22], ["multi-lineage differentiation capabilities", "OBSERVATION", 75, 117], ["anti-inflammatory", "OBSERVATION_MODIFIER", 129, 146]]], ["MSCs have been shown to have efficacy in various models of acute and chronic inflammatory diseases [2] and are now emerging as promising cell-based therapeutics for ALI/ARDS.", [["MSCs", "ANATOMY", 0, 4], ["cell", "ANATOMY", 137, 141], ["ALI", "DISEASE", 165, 168], ["ARDS", "DISEASE", 169, 173], ["MSCs", "CELL", 0, 4], ["cell", "CELL", 137, 141], ["MSCs", "CELL_TYPE", 0, 4], ["MSCs", "PROBLEM", 0, 4], ["acute and chronic inflammatory diseases", "PROBLEM", 59, 98], ["ALI", "PROBLEM", 165, 168], ["ARDS", "PROBLEM", 169, 173], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["inflammatory", "OBSERVATION", 77, 89], ["ARDS", "OBSERVATION", 169, 173]]]], "2148c7f5764ed46065da26594e01b916e5a3e77d": [["IntroductionCoronavirus disease is an infectious disease caused by acute respiratory syndrome coronavirus-2 (SARS-CoV-2).", [["Coronavirus disease", "DISEASE", 12, 31], ["infectious disease", "DISEASE", 38, 56], ["acute respiratory syndrome coronavirus", "DISEASE", 67, 105], ["acute respiratory syndrome coronavirus-2", "ORGANISM", 67, 107], ["SARS-CoV-2", "ORGANISM", 109, 119], ["SARS-CoV-2", "SPECIES", 109, 119], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["an infectious disease", "PROBLEM", 35, 56], ["acute respiratory syndrome coronavirus", "PROBLEM", 67, 105], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["Coronavirus disease", "OBSERVATION", 12, 31], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["respiratory syndrome", "OBSERVATION", 73, 93]]], ["According to the world health organization, the current COVID-19 pandemic sums up to more than 24 million confirmed infections worldwide, and more than 800,000 deaths have been attributed to COVID-19 (www.covid19.who.int).", [["infections", "DISEASE", 116, 126], ["deaths", "DISEASE", 160, 166], ["the current COVID", "TEST", 44, 61], ["pandemic sums", "PROBLEM", 65, 78], ["infections", "PROBLEM", 116, 126], ["COVID", "TEST", 191, 196], ["infections", "OBSERVATION", 116, 126]]], ["Preexisting cardiovascular disease (CVD) seems to increase susceptibility for COVID-19 disease, and 8-12% of patients with COVID- 19 have been reported to develop cardiac injury, increasing to about 20% when patients are referred to intensive care units [1] [2] [3] [4] .", [["cardiovascular", "ANATOMY", 12, 26], ["cardiac", "ANATOMY", 163, 170], ["cardiovascular disease", "DISEASE", 12, 34], ["CVD", "DISEASE", 36, 39], ["cardiac injury", "DISEASE", 163, 177], ["cardiovascular", "ANATOMICAL_SYSTEM", 12, 26], ["patients", "ORGANISM", 109, 117], ["cardiac", "ORGAN", 163, 170], ["patients", "ORGANISM", 208, 216], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 254, 269], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 208, 216], ["Preexisting cardiovascular disease", "PROBLEM", 0, 34], ["CVD", "PROBLEM", 36, 39], ["COVID-19 disease", "PROBLEM", 78, 94], ["COVID", "TEST", 123, 128], ["cardiac injury", "PROBLEM", 163, 177], ["cardiovascular", "ANATOMY", 12, 26], ["disease", "OBSERVATION", 27, 34], ["cardiac", "ANATOMY", 163, 170], ["injury", "OBSERVATION", 171, 177]]], ["In addition, cases of COVID-19 associated myocarditis and stress cardiomyopathy, and increased mortality of patients with impaired LV-and RV-function with COVID-19 have been reported [5] [6] [7] .", [["LV", "ANATOMY", 131, 133], ["COVID-19", "CHEMICAL", 22, 30], ["myocarditis", "DISEASE", 42, 53], ["stress cardiomyopathy", "DISEASE", 58, 79], ["impaired LV-and RV-function", "DISEASE", 122, 149], ["COVID-19", "CHEMICAL", 155, 163], ["COVID-19", "CHEMICAL", 155, 163], ["COVID-19", "GENE_OR_GENE_PRODUCT", 22, 30], ["patients", "ORGANISM", 108, 116], ["LV", "MULTI-TISSUE_STRUCTURE", 131, 133], ["COVID-19", "SIMPLE_CHEMICAL", 155, 163], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 183, 194], ["patients", "SPECIES", 108, 116], ["COVID", "TEST", 22, 27], ["myocarditis", "PROBLEM", 42, 53], ["stress cardiomyopathy", "PROBLEM", 58, 79], ["increased mortality", "PROBLEM", 85, 104], ["impaired LV", "PROBLEM", 122, 133], ["COVID", "TEST", 155, 160], ["myocarditis", "OBSERVATION", 42, 53], ["stress cardiomyopathy", "OBSERVATION", 58, 79], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["LV", "ANATOMY", 131, 133], ["RV", "ANATOMY", 138, 140]]], ["Furthermore, increased detection and worse outcome of PE in patients with proven or suspected COVID-19 disease have been reported [8, 9] .", [["PE", "DISEASE", 54, 56], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["increased detection", "PROBLEM", 13, 32], ["PE", "PROBLEM", 54, 56], ["suspected COVID-19 disease", "PROBLEM", 84, 110], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["PE", "OBSERVATION", 54, 56]]], ["Thus, COVID-19 may directly impact cardiovascular disease and outcomes, and a bi-directional association between COVID-19 and CVD may exist where one increases and worsens the prognosis of the other [2, 10] .IntroductionBeyond direct effects of COVID- 19 , several studies have shown that pandemic-induced but virus-independent effects lead to reduced hospital admissions for acute coronary syndrome (ACS), MI or PE, compared to admission rates before onset of the pandemic or compared to previous years [9, [11] [12] [13] .", [["cardiovascular", "ANATOMY", 35, 49], ["coronary", "ANATOMY", 382, 390], ["COVID-19", "CHEMICAL", 6, 14], ["cardiovascular disease", "DISEASE", 35, 57], ["CVD", "DISEASE", 126, 129], ["acute coronary syndrome", "DISEASE", 376, 399], ["ACS", "DISEASE", 401, 404], ["MI", "DISEASE", 407, 409], ["PE", "DISEASE", 413, 415], ["COVID- 19", "CHEMICAL", 245, 254], ["COVID-19", "GENE_OR_GENE_PRODUCT", 6, 14], ["cardiovascular", "ANATOMICAL_SYSTEM", 35, 49], ["COVID-19", "GENE_OR_GENE_PRODUCT", 113, 121], ["COVID-19", "PROTEIN", 6, 14], ["COVID", "TEST", 6, 11], ["cardiovascular disease", "PROBLEM", 35, 57], ["COVID", "TEST", 113, 118], ["CVD", "PROBLEM", 126, 129], ["COVID", "TEST", 245, 250], ["several studies", "TEST", 257, 272], ["pandemic", "PROBLEM", 289, 297], ["virus", "PROBLEM", 310, 315], ["acute coronary syndrome", "PROBLEM", 376, 399], ["ACS", "PROBLEM", 401, 404], ["MI", "PROBLEM", 407, 409], ["PE", "PROBLEM", 413, 415], ["the pandemic", "PROBLEM", 461, 473], ["cardiovascular disease", "OBSERVATION", 35, 57], ["coronary", "ANATOMY", 382, 390], ["syndrome", "OBSERVATION", 391, 399], ["PE", "OBSERVATION", 413, 415]]], ["Controversy exists however, whether this decrease in admissions during the pandemic is associated with a parallel increase in mortality or complications, or whether these remain unaffected [14] [15] [16] [17] .", [["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 189, 208], ["a parallel increase in mortality", "PROBLEM", 103, 135], ["complications", "PROBLEM", 139, 152], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["increase", "OBSERVATION_MODIFIER", 114, 122]]], ["Given the significant incidence of acute coronary events and PE in the general population, a thorough evaluation of the frequency and potential causes of complications and mortality of cardiovascular emergencies is imperative to assess overall virus-dependent and-independent impact on cardiovascular emergencies during the COVID-19 associated pandemic.", [["coronary", "ANATOMY", 41, 49], ["cardiovascular", "ANATOMY", 185, 199], ["cardiovascular", "ANATOMY", 286, 300], ["PE", "DISEASE", 61, 63], ["cardiovascular emergencies", "DISEASE", 185, 211], ["cardiovascular emergencies", "DISEASE", 286, 312], ["COVID-19", "CHEMICAL", 324, 332], ["coronary", "MULTI-TISSUE_STRUCTURE", 41, 49], ["cardiovascular", "ANATOMICAL_SYSTEM", 185, 199], ["cardiovascular", "ANATOMICAL_SYSTEM", 286, 300], ["acute coronary events", "PROBLEM", 35, 56], ["PE", "PROBLEM", 61, 63], ["a thorough evaluation", "TEST", 91, 112], ["complications", "PROBLEM", 154, 167], ["cardiovascular emergencies", "PROBLEM", 185, 211], ["overall virus", "PROBLEM", 236, 249], ["the COVID", "TEST", 320, 329], ["pandemic", "PROBLEM", 344, 352], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["coronary", "ANATOMY", 41, 49], ["PE", "OBSERVATION", 61, 63]]], ["In the current study, we performed a real-world analysis comparing admission rates, complications and mortality of selected pre-defined life-threatening cardiovascular emergencies (MI, PE, AAD) during and outside of strict COVID-19 associated RM by interrogating a patient information system covering more than 85% of acute hospital admissions in the state of Styria, Austria, comprising a general population of about 1.24 million people.Study designIn Styria, a patient information system is installed to optimize communication and information transfer of health data among hospitals.", [["cardiovascular", "ANATOMY", 153, 167], ["cardiovascular emergencies", "DISEASE", 153, 179], ["MI", "DISEASE", 181, 183], ["PE", "DISEASE", 185, 187], ["AAD", "DISEASE", 189, 192], ["patient", "ORGANISM", 265, 272], ["people", "ORGANISM", 431, 437], ["patient", "ORGANISM", 463, 470], ["patient", "SPECIES", 265, 272], ["people", "SPECIES", 431, 437], ["patient", "SPECIES", 463, 470], ["the current study", "TEST", 3, 20], ["complications", "PROBLEM", 84, 97], ["MI", "PROBLEM", 181, 183], ["PE", "PROBLEM", 185, 187], ["AAD", "PROBLEM", 189, 192], ["PE", "OBSERVATION", 185, 187], ["acute", "OBSERVATION_MODIFIER", 318, 323]]], ["It manages health data of 11 hospitals and hospital alliances, thereby covering more than 85% of acute hospital admissions and 100% of cardiac interventions in Styria, harboring a total population of about 1.24 million people (www. statistik.at).", [["cardiac", "ANATOMY", 135, 142], ["cardiac", "ORGAN", 135, 142], ["people", "ORGANISM", 219, 225], ["people", "SPECIES", 219, 225], ["cardiac interventions", "TREATMENT", 135, 156], ["cardiac", "ANATOMY", 135, 142]]], ["Using this database, we performed a retrospective analysis of pre-defined ICD-10 diagnosis codes indicating hospital admission for MI (I21, I22), PE (I26), and AAD (I71) during the six weeks following onset of mandatory COVID-19 associated RM in Styria (March 16 th to April 26 th 2020), during the six weeks before onset of RM (February 3 rd to March 15 th 2020), and during equivalent time frames (6 calendar weeks) in the years 2016 (March 21 st to May 1 st ), 2017 (March 20 th to April 30 th ), 2018 (March 19 th to April 29 th ), and 2019 (March 18 th to April 28 th ).", [["MI", "DISEASE", 131, 133], ["PE", "DISEASE", 146, 148], ["AAD", "DISEASE", 160, 163], ["March 18 th to April 28 th", "DNA", 546, 572], ["a retrospective analysis", "TEST", 34, 58], ["pre-defined ICD", "TREATMENT", 62, 77], ["MI", "PROBLEM", 131, 133], ["PE", "PROBLEM", 146, 148], ["AAD", "PROBLEM", 160, 163], ["mandatory COVID", "TEST", 210, 225], ["PE", "OBSERVATION", 146, 148]]], ["Patients matching any of these ICD-10 codes were individually analyzed by patient chart review to confirm that the day of admission matched the exploration period, that the ICD-10 code matched the diagnosis, that the ICD-10-encoded diagnosis was the primary reason for hospital admission, and to extract information on complications and mortality.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 74, 81], ["ICD-10", "DNA", 217, 223], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 74, 81], ["these ICD", "TREATMENT", 25, 34], ["the ICD", "TREATMENT", 169, 176], ["the ICD", "TREATMENT", 213, 220], ["complications", "PROBLEM", 319, 332]]], ["The research ethics board of the Medical University of Graz provided ethics approval for the study (32-413 ex 19/20).", [["the study", "TEST", 89, 98]]], ["All patient data were anonymized before accessing the database, and the ethics committee waived the requirement for informed consent.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Patient records were accessed between May 11th and May 19th.", [["Patient", "SPECIES", 0, 7]]], ["All the authors vouch for the completeness and accuracy of the data and the analyses.DefinitionsInclusion of patients matching I21 was restricted to myocardial infarctions related to an acute atherosclerotic cause.", [["myocardial", "ANATOMY", 149, 159], ["atherosclerotic", "ANATOMY", 192, 207], ["myocardial infarctions", "DISEASE", 149, 171], ["atherosclerotic", "DISEASE", 192, 207], ["patients", "ORGANISM", 109, 117], ["myocardial", "MULTI-TISSUE_STRUCTURE", 149, 159], ["patients", "SPECIES", 109, 117], ["the data", "TEST", 59, 67], ["the analyses", "TEST", 72, 84], ["patients matching I21", "PROBLEM", 109, 130], ["myocardial infarctions", "PROBLEM", 149, 171], ["an acute atherosclerotic cause", "PROBLEM", 183, 213], ["myocardial", "ANATOMY", 149, 159], ["infarctions", "OBSERVATION", 160, 171], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["atherosclerotic", "OBSERVATION", 192, 207]]], ["MI was diagnosed and classified (STEMI, NSTEMI) according to the most recent ESC guidelines on diagnosis and treatment of STEMI and NSTE-ACS [18, 19] .", [["MI", "DISEASE", 0, 2], ["STEMI", "DISEASE", 33, 38], ["NSTEMI", "DISEASE", 40, 46], ["STEMI", "DISEASE", 122, 127], ["NSTE", "DISEASE", 132, 136], ["ACS", "DISEASE", 137, 140], ["MI", "PROBLEM", 0, 2], ["STEMI", "PROBLEM", 33, 38], ["NSTEMI", "PROBLEM", 40, 46], ["STEMI", "PROBLEM", 122, 127], ["NSTE", "TEST", 132, 136], ["ACS", "TEST", 137, 140], ["STEMI", "OBSERVATION", 122, 127]]], ["In order not to miss any MI that were encoded with a different ICD-10 code than I21, I22 was included in the screening reflecting subsequent STEMI and NSTEMI.", [["MI", "DISEASE", 25, 27], ["STEMI", "DISEASE", 141, 146], ["NSTEMI", "DISEASE", 151, 157], ["ICD-10 code", "DNA", 63, 74], ["any MI", "PROBLEM", 21, 27], ["a different ICD", "TREATMENT", 51, 66], ["the screening", "TEST", 105, 118], ["subsequent STEMI", "PROBLEM", 130, 146], ["NSTEMI", "PROBLEM", 151, 157], ["STEMI", "OBSERVATION", 141, 146], ["NSTEMI", "OBSERVATION", 151, 157]]], ["To evaluate clinical outcomes of MI patients, we analyzed whether patients (1) suffered cardiogenic shock before, during or shortly after cardiac intervention, or during non-invasive treatment, (2) required CPR before or during cardiac intervention, or during conservative treatment, or (3) died following admission to the hospital and death was attributed to consequences of MI.", [["cardiac", "ANATOMY", 138, 145], ["cardiac", "ANATOMY", 228, 235], ["MI", "DISEASE", 33, 35], ["cardiogenic shock", "DISEASE", 88, 105], ["death", "DISEASE", 336, 341], ["MI", "DISEASE", 376, 378], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 66, 74], ["cardiac", "ORGAN", 138, 145], ["cardiac", "ORGAN", 228, 235], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 66, 74], ["MI", "PROBLEM", 33, 35], ["cardiogenic shock", "PROBLEM", 88, 105], ["cardiac intervention", "TREATMENT", 138, 158], ["non-invasive treatment", "TREATMENT", 170, 192], ["CPR", "TREATMENT", 207, 210], ["cardiac intervention", "TREATMENT", 228, 248], ["conservative treatment", "TREATMENT", 260, 282], ["death", "PROBLEM", 336, 341], ["MI", "PROBLEM", 376, 378], ["cardiogenic", "OBSERVATION_MODIFIER", 88, 99], ["shock", "OBSERVATION", 100, 105], ["MI", "OBSERVATION", 376, 378]]], ["PE patients were identified by screening for ICD-10 code I26.", [["PE", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["PE", "PROBLEM", 0, 2], ["ICD", "TREATMENT", 45, 48]]], ["Definitive diagnosis of PE required conformation by computerized tomography (CT) pulmonary angiogram, ventilation/perfusion scan, or autopsy.", [["pulmonary", "ANATOMY", 81, 90], ["pulmonary", "ORGAN", 81, 90], ["PE", "PROBLEM", 24, 26], ["computerized tomography (CT)", "TEST", 52, 80], ["pulmonary angiogram", "TEST", 81, 100], ["ventilation/perfusion scan", "TEST", 102, 128], ["autopsy", "TEST", 133, 140], ["PE", "OBSERVATION", 24, 26], ["pulmonary", "ANATOMY", 81, 90]]], ["To evaluate clinical outcomes of PE, we analyzed whether patients (1) had signs of right heart dysfunction and increased right ventricular pressure using echocardiography or CT, or (2) required thrombolysis, or (3) died following admission to the hospital and death was attributed to consequences of PE.", [["right heart", "ANATOMY", 83, 94], ["right ventricular", "ANATOMY", 121, 138], ["PE", "DISEASE", 33, 35], ["heart dysfunction", "DISEASE", 89, 106], ["death", "DISEASE", 260, 265], ["PE", "DISEASE", 300, 302], ["patients", "ORGANISM", 57, 65], ["heart", "ORGAN", 89, 94], ["ventricular", "MULTI-TISSUE_STRUCTURE", 127, 138], ["patients", "SPECIES", 57, 65], ["PE", "PROBLEM", 33, 35], ["right heart dysfunction", "PROBLEM", 83, 106], ["increased right ventricular pressure", "PROBLEM", 111, 147], ["echocardiography", "TEST", 154, 170], ["CT", "TEST", 174, 176], ["thrombolysis", "TREATMENT", 194, 206], ["death", "PROBLEM", 260, 265], ["PE", "PROBLEM", 300, 302], ["PE", "OBSERVATION", 33, 35], ["right", "ANATOMY_MODIFIER", 83, 88], ["heart", "ANATOMY", 89, 94], ["dysfunction", "OBSERVATION", 95, 106], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["right ventricular", "ANATOMY", 121, 138], ["pressure", "OBSERVATION_MODIFIER", 139, 147], ["PE", "OBSERVATION", 300, 302]]], ["AAD patients were identified by screening for ICD-10 code I71, and definitive diagnosis of AAD required conformation by CT angiography.", [["AAD", "DISEASE", 0, 3], ["AAD", "DISEASE", 91, 94], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["ICD", "TREATMENT", 46, 49], ["AAD", "PROBLEM", 91, 94], ["CT angiography", "TEST", 120, 134]]], ["The following exclusion criteria were predefined: Incorrect ICD code; admission outside the exploration period; non-atherosclerotic MI; unstable angina; accidental diagnosis; diagnosis not reason for admission; traumatic dissection; age under 18 years of age.Statistical analysisThe characteristics of the patients are reported as mean (standard deviation, SD) and median (interquartile range) for continuous variables, and the number and percentages are given for categorical variables.", [["MI", "DISEASE", 132, 134], ["unstable angina", "DISEASE", 136, 151], ["traumatic dissection", "DISEASE", 211, 231], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["non-atherosclerotic MI", "PROBLEM", 112, 134], ["unstable angina", "PROBLEM", 136, 151], ["traumatic dissection", "PROBLEM", 211, 231], ["Statistical analysis", "TEST", 259, 279], ["median (interquartile range)", "TREATMENT", 365, 393], ["continuous variables", "TEST", 398, 418], ["non-atherosclerotic", "OBSERVATION_MODIFIER", 112, 131], ["MI", "OBSERVATION", 132, 134], ["unstable", "OBSERVATION_MODIFIER", 136, 144], ["angina", "OBSERVATION", 145, 151], ["dissection", "OBSERVATION", 221, 231]]], ["The study period (= 2020 during restrictive measures; March 16 th to April 26 th 2020, calendar weeks 12-17) was compared to the same six calendar weeks in the previous four years (2016-2019) or to the six weeks before onset of RM in 2020.", [["restrictive measures", "TREATMENT", 32, 52]]], ["Rate ratios (RR) and 95% confidence intervals are presented for admissions for MI, PE, and AAD, as well as for patient characteristics, complications and mortality.", [["MI", "DISEASE", 79, 81], ["PE", "DISEASE", 83, 85], ["AAD", "DISEASE", 91, 94], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["Rate ratios", "TEST", 0, 11], ["RR", "TEST", 13, 15], ["MI", "PROBLEM", 79, 81], ["PE", "PROBLEM", 83, 85], ["AAD", "PROBLEM", 91, 94], ["complications", "PROBLEM", 136, 149], ["PE", "OBSERVATION", 83, 85]]], ["All statistical analyses were performed with R version 3.6.1, with a two-sided p-value of 0.05 being considered significant.", [["All statistical analyses", "TEST", 0, 24], ["R version", "TEST", 45, 54], ["a two-sided p-value", "TEST", 67, 86]]], ["No adjustment for multiple testing was done.ResultsHospital admissions for MI, PE, and AAD that occurred during the first six weeks following onset of COVID-19 associated RM in Styria were quantified, analyzed, and compared to admissions that occurred during respective time frames in the years 2016, 2017, 2018, and 2019, or to admissions that occurred during the six weeks before onset of RM.", [["MI", "DISEASE", 75, 77], ["PE", "DISEASE", 79, 81], ["AAD", "DISEASE", 87, 90], ["multiple testing", "TEST", 18, 34], ["MI", "PROBLEM", 75, 77], ["PE", "PROBLEM", 79, 81], ["AAD", "PROBLEM", 87, 90], ["COVID", "TEST", 151, 156], ["PE", "OBSERVATION", 79, 81]]], ["As illustrated in Fig 1, screening of the patient information system revealed a total of 3,629 hospital admissions in Styria matching any of the ICD-10 diagnoses I21, I22, I26 or I71.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["the ICD", "TREATMENT", 141, 148], ["ICD", "OBSERVATION", 145, 148]]], ["For 268 cases patient data could not be accessed due to data protection constraints.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["Thus, 3,361 admissions underwent individual analysis for inclusion and exclusion criteria, resulting in a final inclusion of 1,668 patients in this study.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["individual analysis", "TEST", 33, 52], ["exclusion criteria", "TEST", 71, 89], ["this study", "TEST", 143, 153]]], ["Patients were excluded because reason for admission was different from predefined ICD-10 codes of cardiovascular emergencies (816), data were missing (54), admission occurred outside the predefined time periods (706), incorrect diagnosis (26), or cardiovascular event occurred during hospital stay.ResultsCharacteristics of the patients admitted during the study period and previous years are displayed in Table 1 (Table 2 ).", [["cardiovascular", "ANATOMY", 98, 112], ["cardiovascular", "ANATOMY", 247, 261], ["cardiovascular emergencies", "DISEASE", 98, 124], ["Patients", "ORGANISM", 0, 8], ["cardiovascular", "ANATOMICAL_SYSTEM", 98, 112], ["patients", "ORGANISM", 328, 336], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 328, 336], ["cardiovascular emergencies", "TEST", 98, 124], ["cardiovascular event", "PROBLEM", 247, 267], ["the study", "TEST", 353, 362]]], ["Using Poisson regression analysis, the RR for cumulative admissions reflecting the three major lifethreatening cardiovascular emergencies was significantly lower during COVID-19 associated RM compared to previous years (RR 0.77, p<0.001).", [["cardiovascular", "ANATOMY", 111, 125], ["cardiovascular emergencies", "DISEASE", 111, 137], ["Poisson regression analysis", "TEST", 6, 33], ["the RR", "TEST", 35, 41], ["COVID", "TEST", 169, 174], ["RR", "TEST", 220, 222]]], ["This decrease was driven by lower MI admissions (RR 0.77, p = 0.004) ( Table 2) .", [["MI", "DISEASE", 34, 36], ["RR", "TEST", 49, 51], ["p", "TEST", 58, 59], ["decrease", "OBSERVATION_MODIFIER", 5, 13]]], ["A similar decrease was observed for PE admissions, although significance was not achieved (RR 0.79; p = 0.056).", [["A similar decrease", "PROBLEM", 0, 18], ["PE admissions", "PROBLEM", 36, 49], ["RR", "TEST", 91, 93], ["p", "TEST", 100, 101], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["decrease", "OBSERVATION", 10, 18], ["PE", "OBSERVATION", 36, 38]]], ["A decrease in cumulative admissions for MI, PE and AAD was also observed when comparing the study period to the six weeks before onset of RM (272 before RM versus 226 in 2020 during RM; RR 0.83, p = 0.040) (S1 and S2 Tables).", [["MI", "DISEASE", 40, 42], ["PE", "DISEASE", 44, 46], ["AAD", "DISEASE", 51, 54], ["MI", "PROBLEM", 40, 42], ["PE", "PROBLEM", 44, 46], ["AAD", "PROBLEM", 51, 54], ["the study", "TEST", 88, 97], ["RR", "TEST", 186, 188], ["p", "TEST", 195, 196], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["PE", "OBSERVATION", 44, 46]]], ["In each comparison, admission numbers for AAD were low and not different across years ( Table 2, S3 Table) .", [["AAD", "DISEASE", 42, 45], ["AAD", "PROBLEM", 42, 45]]], ["No difference was observed for any admission diagnoses across years when performing subgroup analyses for patients aged 75 years and above, or younger than 75 years (S1 Table) .", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114]]], ["Complications and mortality of cardiovascular emergencies were analyzed.", [["cardiovascular", "ANATOMY", 31, 45], ["cardiovascular emergencies", "DISEASE", 31, 57], ["cardiovascular", "ANATOMICAL_SYSTEM", 31, 45], ["cardiovascular", "ANATOMY", 31, 45]]], ["Intrahospital mortality of cumulative admissions for MI, PE and AAD was 9.7% and thus increased by 65% during COVID-19 associated RM compared to previous years (RR 1.65, p<0.041) (Fig 3) .", [["MI", "DISEASE", 53, 55], ["PE", "DISEASE", 57, 59], ["AAD", "DISEASE", 64, 67], ["MI", "PROBLEM", 53, 55], ["PE", "PROBLEM", 57, 59], ["AAD", "TEST", 64, 67], ["COVID", "TEST", 110, 115], ["RR", "TEST", 161, 163], ["p", "TEST", 170, 171], ["PE", "OBSERVATION", 57, 59]]], ["This increase in mortality was driven by increased MI mortality (RR 1.80, p = 0.042), whereas mortality was not increased for PE (Table 2) .", [["MI", "DISEASE", 51, 53], ["PE", "DISEASE", 126, 128], ["increased MI mortality", "PROBLEM", 41, 63], ["RR", "TEST", 65, 67], ["PE", "PROBLEM", 126, 128], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["PE", "OBSERVATION", 126, 128]]], ["Cardiogenic shock and CPR occurred in similar number of cases across years ( Table 2 ).", [["Cardiogenic shock", "DISEASE", 0, 17], ["Cardiogenic shock", "PROBLEM", 0, 17], ["CPR", "TREATMENT", 22, 25], ["shock", "OBSERVATION", 12, 17]]], ["While cardiogenic shock and CPR appeared more frequent in STEMI than in NSTEMI patients, no significant difference was observed across years within the two subtypes of MI.", [["cardiogenic shock", "DISEASE", 6, 23], ["STEMI", "DISEASE", 58, 63], ["NSTEMI", "DISEASE", 72, 78], ["MI", "DISEASE", 168, 170], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["cardiogenic shock", "PROBLEM", 6, 23], ["CPR", "TEST", 28, 31], ["STEMI", "PROBLEM", 58, 63], ["significant difference", "PROBLEM", 92, 114], ["MI", "PROBLEM", 168, 170], ["shock", "OBSERVATION", 18, 23], ["more", "OBSERVATION_MODIFIER", 41, 45], ["frequent", "OBSERVATION_MODIFIER", 46, 54], ["no", "UNCERTAINTY", 89, 91], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["MI", "OBSERVATION", 168, 170]]], ["Patients admitted for PE more often received thrombolytic treatment during COVID-19 associated RM compared to previous years (RR 3.63, p = 0.006), although RV dysfunction was observed at similar rates across years.", [["RV", "ANATOMY", 156, 158], ["PE", "DISEASE", 22, 24], ["COVID-19", "CHEMICAL", 75, 83], ["RV dysfunction", "DISEASE", 156, 170], ["Patients", "ORGANISM", 0, 8], ["RV", "PATHOLOGICAL_FORMATION", 156, 158], ["Patients", "SPECIES", 0, 8], ["PE", "PROBLEM", 22, 24], ["thrombolytic treatment", "TREATMENT", 45, 67], ["COVID", "TEST", 75, 80], ["RR", "TEST", 126, 128], ["p", "TEST", 135, 136], ["RV dysfunction", "PROBLEM", 156, 170], ["PE", "OBSERVATION", 22, 24], ["RV", "ANATOMY", 156, 158], ["dysfunction", "OBSERVATION", 159, 170]]], ["When comparing the study period to the six weeks before onset of RM, a similar trend towards increased mortality for cumulative admissions was observed (1.39, p = 0.289) although significance was not achieved (S3 Table) .DiscussionGiven that time from symptoms to first medical contact was longer during the COVID-19 pandemic in other studies [20] , we speculate that the increase of intrahospital mortality in our study despite fewer admissions during COVID-19 associated RM may result from a delay in seeking medical assistance.", [["COVID-19", "CHEMICAL", 453, 461], ["the study", "TEST", 15, 24], ["symptoms", "PROBLEM", 252, 260], ["the COVID", "TEST", 304, 313], ["our study", "TEST", 411, 420], ["increase", "OBSERVATION_MODIFIER", 372, 380]]], ["This may have prevented timely therapeutic intervention and ultimately increased mortality.", [["timely therapeutic intervention", "TREATMENT", 24, 55], ["ultimately increased mortality", "PROBLEM", 60, 90], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["mortality", "OBSERVATION_MODIFIER", 81, 90]]], ["The increase in mortality is likely not explained by direct cardiac effects of COVID-19 disease, since 1) only 6.2% of patients admitted for cardiovascular emergencies and tested for COVID-19 had a concomitant SARS-CoV-2 infection, 2) the death of only one of five SARS-CoV-2 positive patients does not explain an increase of 65% in mortality, and 3) the increase in mortality was driven by MI patients, and none of the patients with MI-related deaths tested for SARS-CoV-2 was positive for SARS-CoV-2.", [["cardiac", "ANATOMY", 60, 67], ["cardiovascular", "ANATOMY", 141, 155], ["cardiovascular emergencies", "DISEASE", 141, 167], ["SARS-CoV-2 infection", "DISEASE", 210, 230], ["death", "DISEASE", 239, 244], ["SARS", "DISEASE", 265, 269], ["MI", "DISEASE", 391, 393], ["MI", "DISEASE", 434, 436], ["deaths", "DISEASE", 445, 451], ["SARS", "DISEASE", 463, 467], ["SARS", "DISEASE", 491, 495], ["cardiac", "ORGAN", 60, 67], ["patients", "ORGANISM", 119, 127], ["SARS-CoV-2", "ORGANISM", 265, 275], ["patients", "ORGANISM", 285, 293], ["patients", "ORGANISM", 394, 402], ["patients", "ORGANISM", 420, 428], ["SARS-CoV-2", "ORGANISM", 463, 473], ["SARS-CoV-2", "ORGANISM", 491, 501], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 285, 293], ["patients", "SPECIES", 394, 402], ["patients", "SPECIES", 420, 428], ["SARS-CoV", "SPECIES", 463, 471], ["SARS-CoV", "SPECIES", 491, 499], ["The increase in mortality", "PROBLEM", 0, 25], ["COVID-19 disease", "PROBLEM", 79, 95], ["cardiovascular emergencies", "TEST", 141, 167], ["COVID", "TEST", 183, 188], ["a concomitant SARS", "PROBLEM", 196, 214], ["CoV-2 infection", "PROBLEM", 215, 230], ["the death", "PROBLEM", 235, 244], ["five SARS", "TEST", 260, 269], ["CoV", "TEST", 270, 273], ["the increase in mortality", "PROBLEM", 351, 376], ["MI", "PROBLEM", 434, 436], ["related deaths", "PROBLEM", 437, 451], ["SARS", "PROBLEM", 463, 467], ["CoV", "TEST", 468, 471], ["SARS", "PROBLEM", 491, 495], ["CoV", "TEST", 496, 499], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["likely not explained", "UNCERTAINTY", 29, 49], ["increase", "OBSERVATION_MODIFIER", 314, 322], ["increase", "OBSERVATION_MODIFIER", 355, 363]]], ["In addition to increased intrahospital mortality of cardiovascular emergency admissions in our study, a 58% increase of out-of-hospital cardiac arrests with a concomitant rise of out-of-hospital deaths was reported during the COVID-19 pandemic [21] , and increased out-of-hospital unexplained deaths had 3-fold higher diagnoses of pulmonary embolism during the COVID-19 pandemic, suggesting that overall numbers of complications and mortality due to cardiovascular emergencies are even higher.", [["cardiovascular", "ANATOMY", 52, 66], ["cardiac", "ANATOMY", 136, 143], ["pulmonary", "ANATOMY", 331, 340], ["cardiovascular", "ANATOMY", 450, 464], ["cardiac arrests", "DISEASE", 136, 151], ["deaths", "DISEASE", 195, 201], ["deaths", "DISEASE", 293, 299], ["pulmonary embolism", "DISEASE", 331, 349], ["cardiovascular emergencies", "DISEASE", 450, 476], ["cardiac", "ORGAN", 136, 143], ["pulmonary", "ORGAN", 331, 340], ["our study", "TEST", 91, 100], ["the COVID", "TEST", 222, 231], ["pulmonary embolism", "PROBLEM", 331, 349], ["the COVID", "TEST", 357, 366], ["pandemic", "PROBLEM", 370, 378], ["complications", "PROBLEM", 415, 428], ["cardiovascular emergencies", "PROBLEM", 450, 476], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["intrahospital", "OBSERVATION_MODIFIER", 25, 38], ["increased", "OBSERVATION_MODIFIER", 255, 264], ["pulmonary", "ANATOMY", 331, 340], ["embolism", "OBSERVATION", 341, 349], ["overall", "OBSERVATION_MODIFIER", 396, 403], ["numbers", "OBSERVATION_MODIFIER", 404, 411], ["complications", "OBSERVATION", 415, 428]]], ["The rather low percentage of COVID-19 infections in the general population may again argue against COVID-19 as the sole trigger of increased mortality.", [["infections", "DISEASE", 38, 48], ["COVID-19", "ORGANISM", 29, 37], ["COVID-19", "SPECIES", 29, 37], ["COVID-19 infections", "PROBLEM", 29, 48], ["COVID", "TEST", 99, 104], ["increased mortality", "PROBLEM", 131, 150], ["low", "OBSERVATION_MODIFIER", 11, 14], ["percentage", "OBSERVATION_MODIFIER", 15, 25], ["infections", "OBSERVATION", 38, 48], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["mortality", "OBSERVATION", 141, 150]]], ["Of note, while impaired accessibility of hospitals and limited system capacity has been discussed to contribute to increased mortality [22] , only 48% of intensive care unit capacities and 33% of regular patient care capacities solely dedicated to the treatment of COVID-19 patients were occupied during peak admission times of SARS-CoV-2 positive patients in Styria, implying that the increased mortality of cardiovascular emergency admissions in our study cannot be explained by constraints of the health care system in Styria.", [["cardiovascular", "ANATOMY", 409, 423], ["COVID", "DISEASE", 265, 270], ["SARS", "DISEASE", 328, 332], ["Styria", "DISEASE", 360, 366], ["patient", "ORGANISM", 204, 211], ["patients", "ORGANISM", 274, 282], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 328, 338], ["patients", "ORGANISM", 348, 356], ["cardiovascular", "ANATOMICAL_SYSTEM", 409, 423], ["patient", "SPECIES", 204, 211], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 348, 356], ["limited system capacity", "PROBLEM", 55, 78], ["increased mortality", "PROBLEM", 115, 134], ["COVID", "TEST", 265, 270], ["SARS", "PROBLEM", 328, 332], ["CoV", "TEST", 333, 336], ["our study", "TEST", 448, 457], ["increased", "OBSERVATION_MODIFIER", 386, 395]]], ["Instead, secondary effects that are not directly related to COVID-19 disease such as misinterpretation of symptoms (dyspnea and chest discomfort rather interpreted as sign of respiratory disease by the patient), strict instructions to stay at home, and increased fear of patients to contact SARS-CoV-2 in medical facilities as a consequence of RM and of the impact of the pandemic situation on individual decision making may be responsible for delayed contact with health care professionals.", [["chest", "ANATOMY", 128, 133], ["respiratory", "ANATOMY", 175, 186], ["dyspnea", "DISEASE", 116, 123], ["chest discomfort", "DISEASE", 128, 144], ["respiratory disease", "DISEASE", 175, 194], ["SARS", "DISEASE", 291, 295], ["chest", "ORGANISM_SUBDIVISION", 128, 133], ["patient", "ORGANISM", 202, 209], ["patients", "ORGANISM", 271, 279], ["CoV-2", "ORGANISM", 296, 301], ["patient", "SPECIES", 202, 209], ["patients", "SPECIES", 271, 279], ["COVID-19 disease", "PROBLEM", 60, 76], ["symptoms", "PROBLEM", 106, 114], ["dyspnea", "PROBLEM", 116, 123], ["chest discomfort", "PROBLEM", 128, 144], ["respiratory disease", "PROBLEM", 175, 194], ["chest", "ANATOMY", 128, 133]]], ["Of note, the authors of an analysis of the FITT-STEMI trial reported that pre-clinical logistic structures, including contact-to-ballon times, were preserved during the COVID-19 pandemic in Germany, supporting the concept that delayed admissions may indeed result from hesitation to contact the medical system [23] .", [["an analysis", "TEST", 24, 35], ["the FITT", "TREATMENT", 39, 47], ["STEMI trial", "TREATMENT", 48, 59], ["pre-clinical logistic structures", "PROBLEM", 74, 106]]], ["Avoiding health care may similarly be the reason for less new diagnoses of cancer in the Netherlands since the onset of the COVID-19 pandemic, thereby likely delaying timely therapeutic intervention and also impairing prognosis [24] .", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["cancer", "CANCER", 75, 81], ["cancer", "PROBLEM", 75, 81], ["the COVID", "TEST", 120, 129], ["therapeutic intervention", "TREATMENT", 174, 198], ["cancer", "OBSERVATION", 75, 81]]], ["Finally, a 47% drop in registered new-onset cases of atrial fibrillation was observed during the national lockdown in Denmark.", [["atrial", "ANATOMY", 53, 59], ["atrial fibrillation", "DISEASE", 53, 72], ["atrial", "MULTI-TISSUE_STRUCTURE", 53, 59], ["a 47% drop", "PROBLEM", 9, 19], ["atrial fibrillation", "PROBLEM", 53, 72], ["atrial", "ANATOMY", 53, 59], ["fibrillation", "OBSERVATION", 60, 72]]], ["In the event of prolonged or subsequent lockdowns, the risk of undiagnosed atrial fibrillation may also result in increased complications such as stroke, potentially translating into poorer outcomes in patients with atrial fibrillation during the COVID-19 pandemic [25] .", [["atrial", "ANATOMY", 75, 81], ["atrial", "ANATOMY", 216, 222], ["atrial fibrillation", "DISEASE", 75, 94], ["stroke", "DISEASE", 146, 152], ["atrial fibrillation", "DISEASE", 216, 235], ["atrial", "MULTI-TISSUE_STRUCTURE", 75, 81], ["patients", "ORGANISM", 202, 210], ["atrial", "MULTI-TISSUE_STRUCTURE", 216, 222], ["patients", "SPECIES", 202, 210], ["undiagnosed atrial fibrillation", "PROBLEM", 63, 94], ["increased complications", "PROBLEM", 114, 137], ["stroke", "PROBLEM", 146, 152], ["atrial fibrillation", "PROBLEM", 216, 235], ["the COVID", "TEST", 243, 252], ["atrial", "ANATOMY", 75, 81], ["fibrillation", "OBSERVATION", 82, 94], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["complications", "OBSERVATION", 124, 137], ["atrial", "ANATOMY", 216, 222], ["fibrillation", "OBSERVATION", 223, 235]]], ["Thus, to avoid unintended secondary effects of measures aiming at limiting the spread of SARS-CoV-2 on cardiovascular mortality, cardiologists and other health care practitioners should be alerted to develop complementary personalized approaches of patient care (e.g. hotlines for cardiovascular disease) to counteract the increase in cardiovascular morbidity and mortality that partially outweighs COVID-19 imposed lethality.", [["cardiovascular", "ANATOMY", 103, 117], ["cardiovascular", "ANATOMY", 281, 295], ["cardiovascular", "ANATOMY", 335, 349], ["SARS", "DISEASE", 89, 93], ["cardiovascular disease", "DISEASE", 281, 303], ["cardiovascular", "ANATOMICAL_SYSTEM", 103, 117], ["patient", "ORGANISM", 249, 256], ["cardiovascular", "ANATOMICAL_SYSTEM", 281, 295], ["cardiovascular", "ANATOMICAL_SYSTEM", 335, 349], ["patient", "SPECIES", 249, 256], ["SARS-CoV", "SPECIES", 89, 97], ["measures", "TREATMENT", 47, 55], ["SARS", "PROBLEM", 89, 93], ["cardiovascular disease", "PROBLEM", 281, 303], ["the increase in cardiovascular morbidity", "PROBLEM", 319, 359], ["COVID", "TEST", 399, 404], ["imposed lethality", "PROBLEM", 408, 425], ["increase", "OBSERVATION_MODIFIER", 323, 331], ["cardiovascular", "ANATOMY", 335, 349], ["morbidity", "OBSERVATION", 350, 359]]], ["While reduced admissions for myocardial infarction have been reported by several groups during the COVID-19 pandemic [11] [12] [13] , Scholz and colleagues reported no change in intrahospital mortality for patients admitted for acute STEMI in Germany [23] .", [["myocardial", "ANATOMY", 29, 39], ["myocardial infarction", "DISEASE", 29, 50], ["pandemic", "DISEASE", 108, 116], ["STEMI", "DISEASE", 234, 239], ["myocardial", "MULTI-TISSUE_STRUCTURE", 29, 39], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["myocardial infarction", "PROBLEM", 29, 50], ["the COVID", "TEST", 95, 104], ["acute STEMI", "PROBLEM", 228, 239], ["myocardial", "ANATOMY", 29, 39], ["infarction", "OBSERVATION", 40, 50], ["no", "UNCERTAINTY", 165, 167], ["acute", "OBSERVATION_MODIFIER", 228, 233], ["STEMI", "OBSERVATION", 234, 239]]], ["The discrepancy regarding mortality compared to our study may be related to the fact that their study analysis ended end of March 2020.", [["our study", "TEST", 48, 57], ["their study analysis", "TEST", 90, 110]]], ["However, while light RM were announced in the mid of March 2020 in Germany, a strict lockdown was not initiated until March 22 and lasted until early May 2020.", [["a strict lockdown", "TREATMENT", 76, 93], ["mid", "ANATOMY_MODIFIER", 46, 49]]], ["In contrast, our study investigated the entire period of strict RM in Austria.", [["our study", "TEST", 13, 22], ["strict RM", "OBSERVATION_MODIFIER", 57, 66]]], ["Thus, the difference in study times and coverage of RM may have resulted in a less pronounced decrease in STEMI admissions in the study by Scholz et al. (12,6% versus 23%) and thus potentially also in no change in mortality if emergency calls may have been less delayed compared to our study.", [["STEMI", "DISEASE", 106, 111], ["the study", "TEST", 126, 135], ["our study", "TEST", 282, 291], ["less", "OBSERVATION_MODIFIER", 78, 82], ["pronounced", "OBSERVATION_MODIFIER", 83, 93], ["decrease", "OBSERVATION_MODIFIER", 94, 102], ["STEMI", "OBSERVATION", 106, 111], ["no", "UNCERTAINTY", 201, 203], ["change", "OBSERVATION_MODIFIER", 204, 210]]], ["In addition, different study populations were investigated, which included STEMI and intra-hospital MI in the study by Scholz and colleagues, and STEMI and atherosclerotic NSTEMI patients but not intrahospital MI in our study.", [["STEMI", "DISEASE", 75, 80], ["MI", "DISEASE", 100, 102], ["STEMI", "DISEASE", 146, 151], ["atherosclerotic NSTEMI", "DISEASE", 156, 178], ["MI", "DISEASE", 210, 212], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["different study populations", "TEST", 13, 40], ["STEMI", "PROBLEM", 75, 80], ["intra-hospital MI", "PROBLEM", 85, 102], ["the study", "TEST", 106, 115], ["STEMI", "PROBLEM", 146, 151], ["atherosclerotic NSTEMI", "PROBLEM", 156, 178], ["intrahospital MI", "PROBLEM", 196, 212], ["our study", "TEST", 216, 225], ["STEMI", "ANATOMY", 146, 151], ["atherosclerotic", "OBSERVATION_MODIFIER", 156, 171], ["NSTEMI", "OBSERVATION", 172, 178]]], ["Furthermore, potential effects of regional differences in STEMI admissions and thus also on mortality cannot be excluded [26] .DiscussionA recent study suggests that a fairly high number of false negative results for SARS-CoV-2 infection may be obtained in patients with few or no symptoms during the incubation period using currently available tests, and patients included in our study tested negative for SARS-CoV-2 were usually only tested at admission with no follow-up tests, thus leaving the possibility that an unknown but substantial number of patients may have had undetected SARS-CoV-2 infection [27] .", [["STEMI", "DISEASE", 58, 63], ["SARS", "DISEASE", 217, 221], ["infection", "DISEASE", 228, 237], ["SARS", "DISEASE", 407, 411], ["SARS-CoV-2 infection", "DISEASE", 585, 605], ["SARS-CoV-2", "ORGANISM", 217, 227], ["patients", "ORGANISM", 257, 265], ["patients", "ORGANISM", 356, 364], ["SARS-CoV-2", "ORGANISM", 407, 417], ["patients", "ORGANISM", 552, 560], ["CoV-2", "ORGANISM", 590, 595], ["patients", "SPECIES", 257, 265], ["patients", "SPECIES", 356, 364], ["patients", "SPECIES", 552, 560], ["SARS-CoV", "SPECIES", 217, 225], ["SARS-CoV", "SPECIES", 407, 415], ["DiscussionA recent study", "TEST", 127, 151], ["SARS", "PROBLEM", 217, 221], ["CoV-2 infection", "PROBLEM", 222, 237], ["symptoms", "PROBLEM", 281, 289], ["tests", "TEST", 345, 350], ["our study", "TEST", 377, 386], ["SARS", "PROBLEM", 407, 411], ["CoV", "TEST", 412, 415], ["follow-up tests", "TEST", 464, 479], ["undetected SARS", "PROBLEM", 574, 589], ["CoV-2 infection", "PROBLEM", 590, 605]]], ["Since increased mortality was driven by MI patients, and none of the tested MI patients that survived or died were SARS-CoV-2 positive, it is rather unlikely that a significant amount of patients may have been SARS-CoV-2 positive.", [["MI", "DISEASE", 40, 42], ["MI", "DISEASE", 76, 78], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 79, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["patients", "ORGANISM", 187, 195], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 210, 220], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 187, 195], ["increased mortality", "PROBLEM", 6, 25], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["SARS", "PROBLEM", 210, 214], ["CoV", "TEST", 215, 218], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["mortality", "OBSERVATION", 16, 25], ["rather unlikely", "UNCERTAINTY", 142, 157], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["amount", "OBSERVATION_MODIFIER", 177, 183]]], ["Nevertheless, it remains to be discussed that viral respiratory infections have been proven to increase the risk of ACS as shown for influenza, implying also a potential direct effect of SARS-CoV-2 infections on ACS incidence and outcome during the COVID-19 pandemic [28] .", [["respiratory", "ANATOMY", 52, 63], ["viral respiratory infections", "DISEASE", 46, 74], ["ACS", "DISEASE", 116, 119], ["influenza", "DISEASE", 133, 142], ["infections", "DISEASE", 198, 208], ["ACS", "DISEASE", 212, 215], ["SARS-CoV-2", "ORGANISM", 187, 197], ["viral respiratory infections", "PROBLEM", 46, 74], ["ACS", "PROBLEM", 116, 119], ["influenza", "PROBLEM", 133, 142], ["SARS", "PROBLEM", 187, 191], ["CoV", "PROBLEM", 192, 195], ["2 infections", "PROBLEM", 196, 208], ["ACS incidence", "PROBLEM", 212, 225], ["the COVID", "TEST", 245, 254]]], ["While the incidence of ACS in patients with COVID-19 remains poorly understood, it has been proposed that plaque rupture, coronary spasm or microthrombi owing to systemic inflammation or cytokine storm may trigger ACS in COVID-19 patients [29] .", [["plaque", "ANATOMY", 106, 112], ["coronary", "ANATOMY", 122, 130], ["microthrombi", "ANATOMY", 140, 152], ["ACS", "DISEASE", 23, 26], ["plaque rupture", "DISEASE", 106, 120], ["spasm", "DISEASE", 131, 136], ["microthrombi", "DISEASE", 140, 152], ["inflammation", "DISEASE", 171, 183], ["ACS", "DISEASE", 214, 217], ["COVID-19", "CHEMICAL", 44, 52], ["patients", "ORGANISM", 30, 38], ["plaque", "PATHOLOGICAL_FORMATION", 106, 112], ["coronary", "MULTI-TISSUE_STRUCTURE", 122, 130], ["patients", "ORGANISM", 230, 238], ["cytokine", "PROTEIN", 187, 195], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 230, 238], ["ACS", "PROBLEM", 23, 26], ["COVID", "TEST", 44, 49], ["plaque rupture", "PROBLEM", 106, 120], ["coronary spasm", "PROBLEM", 122, 136], ["microthrombi", "PROBLEM", 140, 152], ["systemic inflammation", "PROBLEM", 162, 183], ["cytokine storm", "PROBLEM", 187, 201], ["ACS", "PROBLEM", 214, 217], ["COVID", "TEST", 221, 226], ["ACS", "OBSERVATION", 23, 26], ["plaque", "OBSERVATION_MODIFIER", 106, 112], ["rupture", "OBSERVATION", 113, 120], ["coronary", "ANATOMY", 122, 130], ["spasm", "OBSERVATION", 131, 136], ["microthrombi", "OBSERVATION", 140, 152]]], ["Activated macrophages may secrete collagenases, thereby degrading the fibrous cap of atherosclerotic plaques, which may lead to plaque rupture; activated macrophages may secrete tissue factor and promote thrombus formation when the plaque ruptures; coronary thrombus formation may also be increased by direct endothelial or vascular injury due to SARS-CoV-2 infection [29] [30] [31] [32] .", [["macrophages", "ANATOMY", 10, 21], ["fibrous cap", "ANATOMY", 70, 81], ["atherosclerotic plaques", "ANATOMY", 85, 108], ["plaque", "ANATOMY", 128, 134], ["macrophages", "ANATOMY", 154, 165], ["tissue", "ANATOMY", 178, 184], ["thrombus", "ANATOMY", 204, 212], ["plaque", "ANATOMY", 232, 238], ["coronary thrombus", "ANATOMY", 249, 266], ["endothelial", "ANATOMY", 309, 320], ["vascular", "ANATOMY", 324, 332], ["atherosclerotic plaques", "DISEASE", 85, 108], ["plaque rupture", "DISEASE", 128, 142], ["thrombus", "DISEASE", 204, 212], ["plaque", "DISEASE", 232, 238], ["coronary thrombus", "DISEASE", 249, 266], ["SARS", "DISEASE", 347, 351], ["infection", "DISEASE", 358, 367], ["macrophages", "CELL", 10, 21], ["collagenases", "GENE_OR_GENE_PRODUCT", 34, 46], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 85, 108], ["plaque", "PATHOLOGICAL_FORMATION", 128, 134], ["macrophages", "CELL", 154, 165], ["tissue factor", "GENE_OR_GENE_PRODUCT", 178, 191], ["thrombus", "PATHOLOGICAL_FORMATION", 204, 212], ["plaque ruptures", "PATHOLOGICAL_FORMATION", 232, 247], ["coronary thrombus", "PATHOLOGICAL_FORMATION", 249, 266], ["endothelial", "CELL", 309, 320], ["vascular", "MULTI-TISSUE_STRUCTURE", 324, 332], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 347, 357], ["[29] [30] [31] [32]", "SIMPLE_CHEMICAL", 368, 387], ["Activated macrophages", "CELL_TYPE", 0, 21], ["collagenases", "PROTEIN", 34, 46], ["activated macrophages", "CELL_TYPE", 144, 165], ["tissue factor", "PROTEIN", 178, 191], ["Activated macrophages", "PROBLEM", 0, 21], ["secrete collagenases", "PROBLEM", 26, 46], ["atherosclerotic plaques", "PROBLEM", 85, 108], ["plaque rupture", "PROBLEM", 128, 142], ["activated macrophages", "PROBLEM", 144, 165], ["secrete tissue factor", "PROBLEM", 170, 191], ["thrombus formation", "PROBLEM", 204, 222], ["the plaque ruptures", "PROBLEM", 228, 247], ["coronary thrombus formation", "PROBLEM", 249, 276], ["direct endothelial or vascular injury", "PROBLEM", 302, 339], ["SARS", "PROBLEM", 347, 351], ["CoV", "TEST", 352, 355], ["infection", "PROBLEM", 358, 367], ["macrophages", "OBSERVATION", 10, 21], ["fibrous cap", "OBSERVATION_MODIFIER", 70, 81], ["atherosclerotic", "OBSERVATION_MODIFIER", 85, 100], ["plaques", "OBSERVATION", 101, 108], ["may lead to", "UNCERTAINTY", 116, 127], ["plaque", "OBSERVATION_MODIFIER", 128, 134], ["rupture", "OBSERVATION", 135, 142], ["thrombus", "OBSERVATION", 204, 212], ["plaque", "OBSERVATION_MODIFIER", 232, 238], ["ruptures", "OBSERVATION", 239, 247], ["coronary", "ANATOMY", 249, 257], ["thrombus", "OBSERVATION", 258, 266], ["may also be", "UNCERTAINTY", 277, 288], ["increased", "OBSERVATION_MODIFIER", 289, 298], ["vascular", "ANATOMY", 324, 332], ["injury", "OBSERVATION", 333, 339]]], ["Thus, we cannot entirely rule out that undetected SARS-CoV-2 infections may have triggered ACS and potentially also contributed to increased mortality in our study cohort.", [["SARS", "DISEASE", 50, 54], ["infections", "DISEASE", 61, 71], ["ACS", "DISEASE", 91, 94], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["undetected SARS", "PROBLEM", 39, 54], ["CoV-2 infections", "PROBLEM", 55, 71], ["ACS", "PROBLEM", 91, 94], ["increased mortality", "PROBLEM", 131, 150], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["mortality", "OBSERVATION", 141, 150]]], ["At least, it remains to be kept in mind that both COVID-19 and secondary effects of the pandemic may impact incidence and/or fatal outcome of MI.DiscussionStudies suggest that PE may be a complication of COVID-19.", [["MI", "DISEASE", 142, 144], ["PE", "DISEASE", 176, 178], ["COVID-19", "CHEMICAL", 204, 212], ["COVID", "TEST", 50, 55], ["MI", "PROBLEM", 142, 144], ["PE", "PROBLEM", 176, 178], ["COVID", "TEST", 204, 209], ["MI", "OBSERVATION", 142, 144], ["PE", "OBSERVATION", 176, 178]]], ["In a retrospective analysis, Bompard et al. detected an overall cumulative incidence of 24% in a total of 135 COVID-19 patients [33] .", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["a retrospective analysis", "TEST", 3, 27], ["overall", "OBSERVATION_MODIFIER", 56, 63], ["cumulative", "OBSERVATION_MODIFIER", 64, 74]]], ["High rates of coexisting PE were also observed in COVID-19 patients admitted to intensive care units, detected after a median stay of 6 days following ICU admission [34, 35] .", [["PE", "DISEASE", 25, 27], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["coexisting PE", "PROBLEM", 14, 27], ["PE", "OBSERVATION", 25, 27]]], ["In contrast, only 7 of 119 patients (5.9%) suffering from H1N1 pneumonia experienced thrombotic vascular events, with only a single case of PE [36], suggesting a much higher association of PE with COVID-19 compared to other viral pneumonias.", [["vascular", "ANATOMY", 96, 104], ["pneumonia", "DISEASE", 63, 72], ["thrombotic vascular events", "DISEASE", 85, 111], ["PE", "DISEASE", 140, 142], ["PE", "DISEASE", 189, 191], ["COVID-19", "CHEMICAL", 197, 205], ["viral pneumonias", "DISEASE", 224, 240], ["patients", "ORGANISM", 27, 35], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["patients", "SPECIES", 27, 35], ["H1N1 pneumonia", "PROBLEM", 58, 72], ["thrombotic vascular events", "PROBLEM", 85, 111], ["PE", "PROBLEM", 140, 142], ["PE", "PROBLEM", 189, 191], ["COVID", "TEST", 197, 202], ["other viral pneumonias", "PROBLEM", 218, 240], ["H1N1", "OBSERVATION_MODIFIER", 58, 62], ["pneumonia", "OBSERVATION", 63, 72], ["thrombotic", "OBSERVATION", 85, 95], ["vascular", "ANATOMY", 96, 104], ["PE", "OBSERVATION", 140, 142], ["PE", "OBSERVATION", 189, 191], ["viral", "OBSERVATION_MODIFIER", 224, 229], ["pneumonias", "OBSERVATION", 230, 240]]], ["In addition to this direct impact of COVID-19 on PE incidence, our study results suggest that also secondary effects of the COVID-19 pandemic may impact treatment and severity of PE.", [["PE", "DISEASE", 179, 181], ["COVID-19", "CHEMICAL", 37, 45], ["COVID-19", "GENE_OR_GENE_PRODUCT", 37, 45], ["PE", "PATHOLOGICAL_FORMATION", 49, 51], ["COVID-19", "ORGANISM", 124, 132], ["COVID", "TEST", 37, 42], ["our study", "TEST", 63, 72], ["the COVID", "TREATMENT", 120, 129], ["treatment", "TREATMENT", 153, 162], ["PE", "PROBLEM", 179, 181], ["PE", "OBSERVATION", 49, 51], ["PE", "OBSERVATION", 179, 181]]], ["While we observed a trend towards reduced hospital admissions for PE (RR 0.78; p = 0.056), the number of systemic thrombolytic treatments for PE was strikingly higher (RR 3.63, p = 0.006), implying more severe courses of PE admissions.", [["PE", "DISEASE", 66, 68], ["PE", "DISEASE", 142, 144], ["PE", "DISEASE", 221, 223], ["PE", "PROBLEM", 66, 68], ["RR", "TEST", 70, 72], ["p", "TEST", 79, 80], ["systemic thrombolytic treatments", "TREATMENT", 105, 137], ["PE", "PROBLEM", 142, 144], ["RR", "TEST", 168, 170], ["p", "TEST", 177, 178], ["PE admissions", "PROBLEM", 221, 234], ["PE", "OBSERVATION", 66, 68], ["systemic", "OBSERVATION_MODIFIER", 105, 113], ["thrombolytic", "OBSERVATION", 114, 126], ["PE", "OBSERVATION", 142, 144], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["PE", "OBSERVATION", 221, 223]]], ["Although not all patients admitted for PE were tested for SARS-CoV-2, the fact that 32 of 75 patients with PE were tested for SARS-CoV-2 and only 2 of these were SARS-CoV-2 positive, suggests that the implied increase in PE severity may not be due to an association with COVID-19, but instead may result from delayed seeking of medical assistance and may be related to pandemic-associated secondary factors as discussed above.", [["PE", "DISEASE", 39, 41], ["SARS", "DISEASE", 58, 62], ["PE", "DISEASE", 107, 109], ["SARS", "DISEASE", 126, 130], ["PE", "DISEASE", 221, 223], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 93, 101], ["SARS-CoV-2", "ORGANISM", 126, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 162, 172], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 126, 134], ["PE", "PROBLEM", 39, 41], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["PE", "PROBLEM", 107, 109], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["SARS", "TEST", 162, 166], ["CoV", "TEST", 167, 170], ["PE severity", "PROBLEM", 221, 232], ["COVID", "TEST", 271, 276], ["pandemic", "PROBLEM", 369, 377], ["secondary factors", "PROBLEM", 389, 406], ["PE", "OBSERVATION", 39, 41], ["PE", "OBSERVATION", 107, 109], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["PE", "OBSERVATION", 221, 223], ["secondary factors", "OBSERVATION", 389, 406]]], ["In fact, dedicated emergency rooms were implemented in most Styrian hospitals during the pandemic, and diagnostic algorithms recommended early CT scans of the thorax and D-dimer testing, suggesting that the trend towards less PE admissions may even be underestimated since more cases of PE may have been detected compared to times before COVID-19.", [["thorax", "ANATOMY", 159, 165], ["PE", "DISEASE", 226, 228], ["PE", "DISEASE", 287, 289], ["thorax", "ORGAN", 159, 165], ["D-dimer", "GENE_OR_GENE_PRODUCT", 170, 177], ["diagnostic algorithms", "TEST", 103, 124], ["early CT scans of the thorax", "TEST", 137, 165], ["D-dimer testing", "TEST", 170, 185], ["PE", "PROBLEM", 287, 289], ["COVID", "TEST", 338, 343], ["thorax", "ANATOMY", 159, 165], ["PE", "OBSERVATION", 287, 289]]], ["In addition, Bram et al. described a 2.5-fold reduction in pediatric bone fractures during the COVID-19 pandemic, indicating a profound reduction in physical activity during the pandemic, which may increase the risk for thromboembolic events [37] .", [["bone", "ANATOMY", 69, 73], ["bone fractures", "DISEASE", 69, 83], ["thromboembolic", "DISEASE", 220, 234], ["bone", "TISSUE", 69, 73], ["a 2.5-fold reduction", "PROBLEM", 35, 55], ["pediatric bone fractures", "PROBLEM", 59, 83], ["the COVID", "TEST", 91, 100], ["pandemic", "PROBLEM", 104, 112], ["a profound reduction in physical activity", "PROBLEM", 125, 166], ["the pandemic", "PROBLEM", 174, 186], ["thromboembolic events", "PROBLEM", 220, 241], ["2.5-fold", "OBSERVATION_MODIFIER", 37, 45], ["reduction", "OBSERVATION_MODIFIER", 46, 55], ["pediatric bone", "ANATOMY", 59, 73], ["fractures", "OBSERVATION", 74, 83], ["profound", "OBSERVATION_MODIFIER", 127, 135], ["reduction", "OBSERVATION_MODIFIER", 136, 145], ["physical activity", "OBSERVATION", 149, 166], ["thromboembolic", "OBSERVATION", 220, 234]]], ["Thus, it may be speculated that during RM an even larger discrepancy may exist between potentially increased PE incidence and decreased use of medical care.", [["PE", "DISEASE", 109, 111], ["increased PE incidence", "PROBLEM", 99, 121], ["medical care", "TREATMENT", 143, 155], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["PE", "OBSERVATION", 109, 111], ["decreased", "OBSERVATION_MODIFIER", 126, 135]]], ["It appears that aged, less physically active and comorbid individuals that are considered at increased risk for a severe course of COVID-19 may be at increased risk for PE and/or related complications both due to SARS-CoV-2 infection itself and also due to secondary pandemic-associated factors that compromise the use of medical care such as RM or fear of coronavirus infection.DiscussionA number of limitations have to be considered.", [["PE", "DISEASE", 169, 171], ["SARS-CoV-2 infection", "DISEASE", 213, 233], ["coronavirus infection", "DISEASE", 357, 378], ["SARS-CoV-2", "ORGANISM", 213, 223], ["coronavirus", "ORGANISM", 357, 368], ["SARS-CoV", "SPECIES", 213, 221], ["comorbid individuals", "PROBLEM", 49, 69], ["COVID", "TEST", 131, 136], ["PE", "PROBLEM", 169, 171], ["related complications", "PROBLEM", 179, 200], ["SARS", "PROBLEM", 213, 217], ["CoV", "PROBLEM", 218, 221], ["2 infection", "PROBLEM", 222, 233], ["secondary pandemic-associated factors", "PROBLEM", 257, 294], ["medical care", "TREATMENT", 322, 334], ["coronavirus infection", "PROBLEM", 357, 378], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["PE", "OBSERVATION", 169, 171], ["infection", "OBSERVATION", 224, 233], ["coronavirus", "OBSERVATION_MODIFIER", 357, 368], ["infection", "OBSERVATION", 369, 378]]], ["About half of all patients whose death was attributed to MI were not tested for SARS-CoV-2 infection, and a recent study suggests that a fairly high number of false negative results may be obtained in patients with few or no symptoms during the incubation period [27] .", [["death", "DISEASE", 33, 38], ["MI", "DISEASE", 57, 59], ["SARS-CoV-2 infection", "DISEASE", 80, 100], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 80, 90], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 201, 209], ["SARS-CoV-2", "SPECIES", 80, 90], ["MI", "PROBLEM", 57, 59], ["SARS", "PROBLEM", 80, 84], ["CoV-2 infection", "PROBLEM", 85, 100], ["a recent study", "TEST", 106, 120], ["symptoms", "PROBLEM", 225, 233], ["infection", "OBSERVATION", 91, 100]]], ["Thus, we cannot entirely exclude a direct contribution of COVID-19 to the increase in mortality.", [["COVID", "TEST", 58, 63], ["increase", "OBSERVATION_MODIFIER", 74, 82]]], ["However, mortality was driven by MI patients, and none of the tested MI patients that survived or died were SARS-CoV-2 positive.", [["MI", "DISEASE", 33, 35], ["MI", "DISEASE", 69, 71], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 72, 80], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 72, 80], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116]]], ["We also cannot reveal why the observed increase in thrombolytic treatments was not accompanied by an increase in right heart dysfunction, since our retrospective analysis did not enable us to reliably analyze individual decision making by the treating physicians.", [["right heart", "ANATOMY", 113, 124], ["heart dysfunction", "DISEASE", 119, 136], ["heart", "ORGAN", 119, 124], ["thrombolytic treatments", "TREATMENT", 51, 74], ["right heart dysfunction", "PROBLEM", 113, 136], ["our retrospective analysis", "TEST", 144, 170], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["thrombolytic", "OBSERVATION", 51, 63], ["increase", "OBSERVATION_MODIFIER", 101, 109], ["right", "ANATOMY_MODIFIER", 113, 118], ["heart", "ANATOMY", 119, 124], ["dysfunction", "OBSERVATION", 125, 136]]], ["Furthermore, 268 patients were excluded before inclusion or exclusion for data protection reasons, and 54 patients were excluded due to incomplete information, thus we cannot exclude a confounding bias due to these exclusions.", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 106, 114], ["data protection", "TEST", 74, 89], ["a confounding bias", "PROBLEM", 183, 201]]], ["Finally, typical limitations of retrospective analyses may potentially apply, including any selection or misclassification bias, unknown confounders, and the hypothesisgenerating character of the study.DiscussionSupporting information S1", [["retrospective analyses", "TEST", 32, 54], ["misclassification bias", "PROBLEM", 105, 127], ["the study", "TEST", 192, 201]]]], "8c248b7ecd86825a3926cd16c51e89bcc7d63aaf": [["Immunotherapy using chimeric antigen receptor (CAR) T-cells for hematologic malignancies and other diagnoses is increasing rapidly [1] .", [["chimeric antigen receptor (CAR) T-cells", "ANATOMY", 20, 59], ["hematologic malignancies", "ANATOMY", 64, 88], ["hematologic malignancies", "DISEASE", 64, 88], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 20, 45], ["CAR", "GENE_OR_GENE_PRODUCT", 47, 50], ["hematologic malignancies", "CANCER", 64, 88], ["chimeric antigen receptor (CAR) T-cells", "CELL_TYPE", 20, 59], ["Immunotherapy", "TREATMENT", 0, 13], ["chimeric antigen receptor", "TEST", 20, 45], ["hematologic malignancies", "PROBLEM", 64, 88]]], ["This approach has resulted in high response rates in children with refractory or relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) [2] [3] [4] .", [["R/R) B-cell acute lymphoblastic leukemia", "ANATOMY", 91, 131], ["B-ALL", "ANATOMY", 133, 138], ["acute lymphoblastic leukemia (B-ALL", "DISEASE", 103, 138], ["children", "ORGANISM", 53, 61], ["B-cell acute lymphoblastic leukemia", "CANCER", 96, 131], ["B-ALL", "CANCER", 133, 138], ["children", "SPECIES", 53, 61], ["high response rates", "PROBLEM", 30, 49], ["refractory or relapsed (R/R) B-cell acute lymphoblastic leukemia", "PROBLEM", 67, 131], ["high response", "OBSERVATION", 30, 43], ["cell", "OBSERVATION", 98, 102], ["acute lymphoblastic leukemia", "OBSERVATION", 103, 131]]], ["The first commercially available CD19 CAR T-cell therapy, tisangenlecleucel (Kymriah), was approved by the Food and Drug Administration in 2017 [5] .", [["T-cell", "ANATOMY", 42, 48], ["tisangenlecleucel", "CHEMICAL", 58, 75], ["Kymriah", "CHEMICAL", 77, 84], ["CD19", "GENE_OR_GENE_PRODUCT", 33, 37], ["tisangenlecleucel", "SIMPLE_CHEMICAL", 58, 75], ["CD19", "PROTEIN", 33, 37], ["CD19 CAR T-cell therapy", "TREATMENT", 33, 56], ["tisangenlecleucel (Kymriah)", "TREATMENT", 58, 85]]]], "PMC4666761": [["As of June 24, 2015, there have been 1354 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 72, 116], ["MERS-CoV) infection", "DISEASE", 118, 137], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 72, 116], ["MERS-CoV", "ORGANISM", 118, 126], ["Middle East respiratory syndrome coronavirus", "SPECIES", 72, 116], ["MERS-CoV", "SPECIES", 118, 126], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 72, 116], ["infection", "PROBLEM", 128, 137], ["Middle", "ANATOMY_MODIFIER", 72, 78], ["respiratory syndrome", "OBSERVATION", 84, 104], ["infection", "OBSERVATION", 128, 137]]], ["In May\u2013June 2015, a large outbreak occurred in the Republic of Korea.", [["a large outbreak", "PROBLEM", 18, 34], ["large", "OBSERVATION_MODIFIER", 20, 25], ["outbreak", "OBSERVATION", 26, 34]]]], "a9b8cedbc75e76fb5d9d8220abc6eb63c3b22a39": [["J o u r n a l P r e -p r o o f 3 The World Health Organization (WHO) declared Coronavirus disease 2019 (COVID-19) as pandemic on March 11, 2020.", [["Coronavirus disease", "DISEASE", 78, 97], ["J", "TEST", 0, 1], ["Coronavirus disease", "PROBLEM", 78, 97], ["COVID", "TEST", 104, 109], ["Coronavirus disease", "OBSERVATION", 78, 97]]], ["Due to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses, we are currently facing a scenario of sustained community transmission of COVID-19 worldwide.", [["acute respiratory syndrome coronavirus", "DISEASE", 34, 72], ["COVID-19", "CHEMICAL", 171, 179], ["SARS-CoV-2", "ORGANISM", 76, 86], ["severe acute respiratory syndrome coronavirus", "SPECIES", 27, 72], ["SARS-CoV-2", "SPECIES", 76, 86], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 27, 72], ["SARS", "PROBLEM", 76, 80], ["viruses", "PROBLEM", 88, 95], ["COVID", "TEST", 171, 176], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["spread", "OBSERVATION_MODIFIER", 17, 23], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["respiratory syndrome coronavirus", "OBSERVATION", 40, 72]]], ["1 Early implementation of mitigation associated with suppression strategies can drastically reduce the number of hospitalizations and deaths.", [["deaths", "DISEASE", 134, 140], ["mitigation", "TREATMENT", 26, 36], ["suppression strategies", "TREATMENT", 53, 75]]], ["2 Large-scale testing, rapid diagnosis and immediate isolation of cases coupled with rigorous tracking and preventive self-isolation of close contacts are essential measures to reduce the burden of the COVID-19 pandemic.", [["Large-scale testing", "TEST", 2, 21], ["immediate isolation of cases", "TREATMENT", 43, 71], ["rigorous tracking", "PROBLEM", 85, 102], ["essential measures", "TREATMENT", 155, 173], ["the COVID", "TEST", 198, 207], ["pandemic", "PROBLEM", 211, 219], ["Large", "OBSERVATION_MODIFIER", 2, 7], ["-scale", "OBSERVATION_MODIFIER", 7, 13]]], ["3 Therefore, tests for COVID-19 should be point-ofcare, widely available, and implemented outside of hospital settings to prevent overwhelming the health care system as well as the risk of nosocomial transmission to other patients and healthcare workers.", [["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["tests", "TEST", 13, 18], ["COVID", "TEST", 23, 28]]], ["Results from the mathematical modelling study performed by the Imperial College of London for Brazil, the implementation of suppression strategies could save up to a million lives and prevent the collapse of the Brazilian Unified Health System (Sistema \u00danico de Sa\u00fade, SUS) compared to an unmitigated strategy.", [["the mathematical modelling study", "TEST", 13, 45], ["suppression strategies", "TREATMENT", 124, 146], ["an unmitigated strategy", "TREATMENT", 286, 309], ["collapse", "OBSERVATION", 196, 204]]], ["4 Though massive testing is a cornerstone to reduce the burden of COVID-19, the accuracy of commercially available tests for COVID-19 in Brazil remains unclear.", [["COVID-19", "CHEMICAL", 125, 133], ["massive testing", "TEST", 9, 24], ["COVID", "TEST", 66, 71], ["tests", "TEST", 115, 120], ["COVID", "TEST", 125, 130], ["massive", "OBSERVATION", 9, 16]]], ["The aim of this study was to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil.", [["this study", "TEST", 11, 21], ["available tests", "TEST", 81, 96], ["COVID", "TEST", 107, 112]]]], "9f318e6ef98bc25471c1e840e9fc94f37c353a51": [["COVID-19 care in India: the course to self-relianceThe public health response to COVID-19 in India has been highly centralised, resulting in a homogenous strategy applied across a sixth of the world's population.", [["COVID-19", "CHEMICAL", 81, 89], ["COVID", "TEST", 81, 86], ["a homogenous strategy", "TREATMENT", 141, 162], ["homogenous", "OBSERVATION_MODIFIER", 143, 153], ["strategy", "OBSERVATION", 154, 162]]], ["In May 2020, the prime minister called upon the Indian people to be self-reliant.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["We discuss here opportunities to modify several aspects of the medical response to echo this sentiment.COVID-19 care in India: the course to self-relianceUntil April 27, 2020, national guidelines required that all symptomatic patients and families be transferred to health-care facilities and isolated away from their homes, and entire neighbourhoods be declared containment zones.", [["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["echo", "TEST", 83, 87]]], ["1 This strategy overwhelmed the health-care system in India's most populous cities, including Mumbai and Delhi, and precluded access for non-COVID care.", [["non-COVID care", "TREATMENT", 137, 151]]], ["2 The resultant fear and stigmatisation has resulted in delays in seeking timely care, and violations of privacy.COVID-19 care in India: the course to self-relianceThere was an initial rush to build new COVID-19 hospitals and secure ventilators.", [["secure ventilators", "TREATMENT", 226, 244], ["resultant", "OBSERVATION_MODIFIER", 6, 15], ["fear", "OBSERVATION", 16, 20]]], ["3 Despite ample scientific evidence against the efficacy of hydroxychloroquine, health departments and physicians continued to promote its use both prophylactically and therapeutically.", [["hydroxychloroquine", "CHEMICAL", 60, 78], ["hydroxychloroquine", "CHEMICAL", 60, 78], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 60, 78], ["hydroxychloroquine", "TREATMENT", 60, 78]]], ["4 State agencies have undertaken population-wide distribution of unproven homeopathic and Ayurvedic medicines and herbal tea mixes (ukalo), claiming they boost immunity and prevent quarantined individuals from getting infected.", [["unproven homeopathic", "TREATMENT", 65, 85], ["Ayurvedic medicines", "TREATMENT", 90, 109], ["herbal tea mixes", "TREATMENT", 114, 130], ["quarantined individuals", "PROBLEM", 181, 204]]], ["5 Practitioners are also prescribing various other medications, including the anti-parasitic drug ivermectin.COVID-19 care in India: the course to self-relianceThe attention on wonder drugs and claims about imminent vaccine availability continue to distract from gaps in testing, contact tracing, and safe work environments.", [["ivermectin", "CHEMICAL", 98, 108], ["ivermectin", "CHEMICAL", 98, 108], ["ivermectin", "SIMPLE_CHEMICAL", 98, 108], ["various other medications", "TREATMENT", 37, 62], ["the anti-parasitic drug ivermectin", "TREATMENT", 74, 108], ["wonder drugs", "TREATMENT", 177, 189], ["imminent vaccine", "TREATMENT", 207, 223], ["gaps in testing", "TEST", 263, 278], ["contact tracing", "TEST", 280, 295]]], ["For months, physicians were barred from testing asymptomatic patients.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["Although India's daily test count has grown exponentially, it remains low, at around 0\u00b735 per 1000 people, as of Aug 5, 2020.", [["people", "SPECIES", 99, 105], ["India's daily test count", "TEST", 9, 33], ["exponentially", "OBSERVATION_MODIFIER", 44, 57], ["low", "OBSERVATION_MODIFIER", 70, 73]]], ["6 To date, publicly shared data are not disaggregated enough to shed light on local incidence, or on the demographic determinants that might explain the low reported infection fatality rate.COVID-19 care in India: the course to self-relianceAnecdotes and personal testimony should be an impetus for rigorous trials, not a license to promote unproven interventions.", [["infection", "DISEASE", 166, 175], ["the low reported infection fatality rate", "PROBLEM", 149, 189], ["rigorous trials", "TREATMENT", 299, 314], ["unproven interventions", "TREATMENT", 341, 363], ["infection", "OBSERVATION", 166, 175]]], ["A flood of articles, models, and mobile device applications (apps) driven by technocrats and consulting companies has resulted in a high noiseto-signal ratio globally.", [["mobile device applications", "TREATMENT", 33, 59]]], ["Policy makers must resist the temptation of quick action, and instead rely on those trained to interpret scientific evidence.COVID-19 care in India: the course to self-relianceMost people with COVID-19 can be cared for at home, and there is no justification for institutionalising those with mild or no symptoms.", [["people", "ORGANISM", 181, 187], ["people", "SPECIES", 181, 187], ["COVID", "TREATMENT", 193, 198], ["symptoms", "PROBLEM", 303, 311], ["no", "UNCERTAINTY", 241, 243]]], ["Where isolation is essential but impossible, dignified quarantine facilities could be constructed in the community, as was done in the densely populated slums of Dharavi in Mumbai, in the absence of which, mandatory use of facial coverings (which could be inexpensively provided), would also play a substantial mitigating role.", [["facial", "ANATOMY", 223, 229]]], ["7 India's general practitioners and community health workers, can effectively monitor a patient's vital signs at home via in-person visits or telemedicine, distribute and encourage the use of masks and soap for handwashing, advise selfpronation, and, when possible, use adjuncts like pulse oximeters.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["masks", "TREATMENT", 192, 197], ["handwashing", "TREATMENT", 211, 222], ["pulse oximeters", "TREATMENT", 284, 299]]], ["8 Providing oxygen therapy (and pronation) in lower tiers of care could avert the need for subsequent ventilation in many patients and help reduce the pressure on hospital bed capacity.", [["oxygen", "CHEMICAL", 12, 18], ["oxygen", "CHEMICAL", 12, 18], ["oxygen", "SIMPLE_CHEMICAL", 12, 18], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["Providing oxygen therapy", "TREATMENT", 2, 26], ["pronation", "TREATMENT", 32, 41], ["subsequent ventilation", "TREATMENT", 91, 113], ["oxygen therapy", "OBSERVATION", 12, 26]]], ["9 Some patients might benefit from steroids, and the small minority of people who clinically deteriorate will need intensive care.", [["steroids", "CHEMICAL", 35, 43], ["steroids", "CHEMICAL", 35, 43], ["patients", "ORGANISM", 7, 15], ["people", "ORGANISM", 71, 77], ["patients", "SPECIES", 7, 15], ["people", "SPECIES", 71, 77], ["steroids", "TREATMENT", 35, 43], ["intensive care", "TREATMENT", 115, 129], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["Liberal use of antivirals should be discouraged, as their benefit is marginal and limited to severe cases, and is cost prohibitive.COVID-19 care in India: the course to self-relianceThere is first-hand evidence to show how the Indian people have risen to the occasion in helping older neighbours quarantine, sharing chores, and stepping in to feed and assist the millions of migrants stranded by the lockdown.", [["people", "ORGANISM", 234, 240], ["people", "SPECIES", 234, 240], ["antivirals", "TREATMENT", 15, 25], ["severe cases", "PROBLEM", 93, 105]]], ["Community-centred guidelines for people to self-organise and self-care must be vigorously disseminated.", [["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39]]], ["Women's empowerment groups in Kerala, for example, were marshalled to map where older people live to ensure they had access to medicine and food while selfquarantining-an acceptable, workable, and scalable solution in the Indian context.", [["Women", "ORGANISM", 0, 5], ["people", "ORGANISM", 86, 92], ["Women", "SPECIES", 0, 5], ["people", "SPECIES", 86, 92]]], ["Symptomatic patients must be treated at home to the extent possible, and in-patient protocols must only use evidence-based interventions; most patients might only require oxygen and pronation.COVID-19 care in India: the course to self-relianceIn summary, what is needed is a plethora of lowtech solutions (especially facial coverings), adherence to science, and societal participation in caring for vulnerable people.", [["facial", "ANATOMY", 317, 323], ["oxygen", "CHEMICAL", 171, 177], ["oxygen", "CHEMICAL", 171, 177], ["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 76, 83], ["patients", "ORGANISM", 143, 151], ["oxygen", "SIMPLE_CHEMICAL", 171, 177], ["people", "ORGANISM", 410, 416], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 76, 83], ["patients", "SPECIES", 143, 151], ["people", "SPECIES", 410, 416], ["evidence-based interventions", "TREATMENT", 108, 136], ["oxygen", "TREATMENT", 171, 177], ["pronation", "TREATMENT", 182, 191], ["lowtech solutions", "TREATMENT", 287, 304]]], ["But there are the people of India.", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24]]]], "PMC4412533": [["IntroductionSince its discovery in Saudi Arabia in 2012, the Middle East respiratory syndrome coronavirus (MERSCoV) has been implicated in 1042 laboratory confirmed cases of human infection, including 419 deaths.", [["respiratory syndrome coronavirus", "DISEASE", 73, 105], ["human infection", "DISEASE", 174, 189], ["deaths", "DISEASE", 205, 211], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 61, 105], ["MERSCoV", "CANCER", 107, 114], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["Middle East respiratory syndrome coronavirus", "SPECIES", 61, 105], ["human", "SPECIES", 174, 179], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 57, 105], ["human infection", "PROBLEM", 174, 189], ["Middle", "ANATOMY_MODIFIER", 61, 67], ["respiratory syndrome", "OBSERVATION", 73, 93], ["infection", "OBSERVATION", 180, 189]]], ["Among these cases, 14 were reported by European countries, including 8 imported cases and 3 local person-to-person transmissions [1].IntroductionThe MERS-CoV genome is comprised of at least 10 putative open reading frames, including 2 that encode the spike (S) and nucleocapsid (N) proteins [2].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 265, 290], ["MERS-CoV genome", "DNA", 149, 164], ["open reading frames", "DNA", 202, 221], ["spike (S) and nucleocapsid (N) proteins", "PROTEIN", 251, 290], ["person", "SPECIES", 98, 104], ["person", "SPECIES", 108, 114], ["MERS-CoV", "SPECIES", 149, 157], ["nucleocapsid (N) proteins", "TEST", 265, 290]]], ["The S and N protein genes have been used for coronavirus genotyping and phylogenetic analyses which have aided our understanding of the virus\u2019s temporal and geographic origins and evolution [3].", [["S and N protein genes", "DNA", 4, 25], ["coronavirus", "SPECIES", 45, 56], ["The S and N protein genes", "TREATMENT", 0, 25], ["coronavirus genotyping", "TEST", 45, 67], ["phylogenetic analyses", "TEST", 72, 93]]], ["The S protein is involved in virus receptor binding and is known to be the main antigenic component to which significant neutralizing antibody responses are induced [4].", [["S protein", "PROTEIN", 4, 13], ["The S protein", "TEST", 0, 13], ["virus receptor binding", "PROBLEM", 29, 51], ["significant neutralizing antibody responses", "PROBLEM", 109, 152], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["neutralizing antibody", "OBSERVATION", 121, 142]]], ["The N protein is a highly immunogenic phosphoprotein implicated in viral genome replication and modulation of cell signaling pathways [5].IntroductionThe present study focused on the laboratory investigation of an imported MERS-CoV case in Greece and its phylogenetic comparison with other recently circulating strains.Materials and MethodsA 69-year-old Greek national presented to a tertiary care hospital in Athens on 17 April 2014 with prolonged fever, diarrhea and pneumonia (onset of symptoms on 8 April).", [["cell", "ANATOMY", 110, 114], ["fever", "DISEASE", 449, 454], ["diarrhea", "DISEASE", 456, 464], ["pneumonia", "DISEASE", 469, 478], ["cell", "CELL", 110, 114], ["MERS-CoV", "ORGANISM", 223, 231], ["N protein", "PROTEIN", 4, 13], ["highly immunogenic phosphoprotein", "PROTEIN", 19, 52], ["MERS-CoV", "SPECIES", 223, 231], ["The N protein", "TEST", 0, 13], ["a highly immunogenic phosphoprotein", "PROBLEM", 17, 52], ["viral genome replication", "TREATMENT", 67, 91], ["cell signaling pathways", "PROBLEM", 110, 133], ["The present study", "TEST", 150, 167], ["the laboratory investigation", "TEST", 179, 207], ["other recently circulating strains", "PROBLEM", 284, 318], ["Materials", "TEST", 319, 328], ["MethodsA", "TEST", 333, 341], ["prolonged fever", "PROBLEM", 439, 454], ["diarrhea", "PROBLEM", 456, 464], ["pneumonia", "PROBLEM", 469, 478], ["symptoms", "PROBLEM", 489, 497], ["viral genome replication", "OBSERVATION", 67, 91], ["cell", "OBSERVATION", 110, 114], ["diarrhea", "OBSERVATION", 456, 464], ["pneumonia", "OBSERVATION", 469, 478]]], ["Because of high suspicion of MERS-CoV infection, two oropharyngeal swab specimens were collected on 17 April (specimen A) and 18 April (specimen B) for laboratory investigation.", [["oropharyngeal swab specimens", "ANATOMY", 53, 81], ["MERS-CoV infection", "DISEASE", 29, 47], ["MERS-CoV", "ORGANISM", 29, 37], ["oropharyngeal swab specimens", "CANCER", 53, 81], ["MERS-CoV", "SPECIES", 29, 37], ["MERS", "PROBLEM", 29, 33], ["CoV infection", "PROBLEM", 34, 47], ["two oropharyngeal swab specimens", "TEST", 49, 81], ["laboratory investigation", "TEST", 152, 176], ["CoV", "OBSERVATION_MODIFIER", 34, 37], ["infection", "OBSERVATION", 38, 47]]], ["The purpose of the urgent clinical care testing needed was explained to the patient and written consent was obtained for potential publication.Materials and MethodsFor molecular detection of MERS-CoV RNA, two real-time RT-PCR (rRT-PCR) assays targeting regions upstream of envelope gene (UpE) and the open reading frame (ORF) 1a were used [7].", [["patient", "ORGANISM", 76, 83], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 191, 199], ["MERS-CoV RNA", "RNA", 191, 203], ["envelope gene", "DNA", 273, 286], ["UpE", "DNA", 288, 291], ["open reading frame (ORF) 1a", "DNA", 301, 328], ["patient", "SPECIES", 76, 83], ["MERS-CoV", "SPECIES", 191, 199], ["the urgent clinical care testing", "TEST", 15, 47], ["molecular detection", "TEST", 168, 187], ["MERS", "TEST", 191, 195], ["CoV RNA", "TEST", 196, 203], ["RT-PCR", "TEST", 219, 225], ["rRT-PCR", "TEST", 227, 234]]], ["Partial sequencing of the RNA-dependent RNA polymerase (RdRp) and N genes and BLAST analysis of the amplicon sequences was also performed as previously described [7].", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 26, 54], ["RNA-dependent RNA polymerase (RdRp) and N genes", "DNA", 26, 73], ["amplicon sequences", "DNA", 100, 118], ["the RNA", "TEST", 22, 29], ["dependent RNA polymerase", "PROBLEM", 30, 54], ["RdRp", "TEST", 56, 60], ["BLAST analysis", "TEST", 78, 92], ["the amplicon sequences", "TEST", 96, 118], ["dependent", "OBSERVATION_MODIFIER", 30, 39], ["RNA polymerase", "OBSERVATION", 40, 54]]], ["A serum sample collected from the patient after six days of hospitalization was available for serological testing using the Anti-MERS Coronavirus Indirect Immunofluoresence kit (Euroimmun, Lubeck, Germany).Materials and MethodsIn addition to partial sequencing, full length ORFs of the S (4042 nt) and N (1242 nt) protein genes were obtained by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, using Sanger sequencing methods and deposited into the GenBank database under accession numbers KJ782550 and KJ782549, respectively.", [["serum sample", "ANATOMY", 2, 14], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["patient", "ORGANISM", 34, 41], ["ORFs", "DNA", 274, 278], ["S", "DNA", 286, 287], ["N (1242 nt) protein genes", "DNA", 302, 327], ["patient", "SPECIES", 34, 41], ["A serum sample", "TEST", 0, 14], ["serological testing", "TEST", 94, 113], ["MethodsIn", "TREATMENT", 220, 229], ["partial sequencing", "TEST", 242, 260], ["the S", "TEST", 282, 287], ["N (1242 nt) protein genes", "TEST", 302, 327], ["Disease Control", "TREATMENT", 361, 376]]], ["Sequences were confirmed independently by two separate CDC laboratories.ResultsThe UpE and ORF-1a rRT-PCR results for specimen A were equivocal [PCR threshold cycle (Ct) value 38.8] and negative, respectively, and the specimen was determined to be inconclusive for MERS-CoV RNA detection.", [["specimen A", "ANATOMY", 118, 128], ["specimen", "ANATOMY", 218, 226], ["UpE", "GENE_OR_GENE_PRODUCT", 83, 86], ["ORF-1a", "GENE_OR_GENE_PRODUCT", 91, 97], ["specimen A", "CANCER", 118, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 265, 273], ["UpE and ORF-1a rRT", "DNA", 83, 101], ["MERS-CoV RNA", "RNA", 265, 277], ["MERS-CoV", "SPECIES", 265, 273], ["The UpE", "TEST", 79, 86], ["ORF", "TEST", 91, 94], ["1a rRT", "TEST", 95, 101], ["PCR", "TEST", 102, 105], ["specimen A", "TEST", 118, 128], ["PCR threshold cycle", "TEST", 145, 164], ["Ct) value", "TEST", 166, 175], ["the specimen", "TEST", 214, 226], ["MERS", "PROBLEM", 265, 269], ["CoV RNA detection", "TEST", 270, 287]]], ["In contrast, specimen B was found to be positive by both UpE and ORF-1a assays with Ct values 30.2 and 32.5, respectively.", [["specimen B", "ANATOMY", 13, 23], ["specimen B", "CELL", 13, 23], ["ORF-1a", "GENE_OR_GENE_PRODUCT", 65, 71], ["ORF", "DNA", 65, 68], ["specimen B", "TEST", 13, 23], ["ORF", "TEST", 65, 68], ["1a assays", "TEST", 69, 78], ["Ct values", "TEST", 84, 93]]], ["The presence of MERS-CoV RNA was also confirmed on specimen B by RT-PCR and partial sequencing of the RdRp and N genes.ResultsFull genome sequencing was not possible due to the limited available sample volume.", [["sample", "ANATOMY", 195, 201], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["MERS-CoV RNA", "RNA", 16, 28], ["RdRp and N genes", "DNA", 102, 118], ["MERS-CoV", "SPECIES", 16, 24], ["MERS", "PROBLEM", 16, 20], ["CoV RNA", "PROBLEM", 21, 28], ["specimen B", "TEST", 51, 61], ["RT", "TEST", 65, 67], ["PCR", "TEST", 68, 71], ["the RdRp", "TREATMENT", 98, 106], ["MERS", "OBSERVATION", 16, 20], ["CoV RNA", "OBSERVATION", 21, 28]]], ["However, sequences of the S and N protein coding regions were successfully obtained.", [["S and N protein coding regions", "DNA", 26, 56], ["the S", "TEST", 22, 27]]], ["The Greece-Saudi Arabia_2014 S differed by 0.1\u20130.9% nucleotides (nt) and 0.1\u20131.3% amino acids (aa) from 68 other published human and camel derived MERS-CoV sequences.", [["amino acids", "CHEMICAL", 82, 93], ["nucleotides", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 82, 93], ["amino acids", "AMINO_ACID", 82, 93], ["human", "ORGANISM", 123, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 147, 155], ["human and camel derived MERS-CoV sequences", "DNA", 123, 165], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["camel", "SPECIES", 133, 138], ["MERS-CoV", "SPECIES", 147, 155], ["nucleotides (nt)", "TREATMENT", 52, 68]]], ["One unique nt change present as a mixed base at position 1533 (G>C) of the S ORF confers a predicted aa change of arginine (R) with proline (P) at position 511 (R511P).", [["arginine", "CHEMICAL", 114, 122], ["proline", "CHEMICAL", 132, 139], ["arginine", "CHEMICAL", 114, 122], ["proline", "CHEMICAL", 132, 139], ["arginine", "AMINO_ACID", 114, 122], ["proline", "AMINO_ACID", 132, 139], ["position 511", "AMINO_ACID", 147, 159], ["S ORF", "DNA", 75, 80], ["proline (P)", "PROTEIN", 132, 143], ["One unique nt change", "PROBLEM", 0, 20], ["a predicted aa change of arginine (R) with proline (P) at position", "TREATMENT", 89, 155], ["nt", "OBSERVATION_MODIFIER", 11, 13], ["change", "OBSERVATION", 14, 20]]], ["The Greece-Saudi Arabia_2014 N differed by 0.1\u20130.9% nt and 0\u20130.8% aa from 69 other published MERS-CoV sequences.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["MERS-CoV sequences", "DNA", 93, 111], ["MERS-CoV", "SPECIES", 93, 101], ["CoV sequences", "TEST", 98, 111]]], ["No unique nt changes were identified.ResultsPhylogenetic analyses of the MERS-CoV S and N ORFs are shown in Fig 1.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["MERS-CoV S and N ORFs", "DNA", 73, 94], ["MERS-CoV", "SPECIES", 73, 81], ["unique nt changes", "PROBLEM", 3, 20], ["the MERS", "TEST", 69, 77], ["CoV S", "TEST", 78, 83], ["N ORFs", "TEST", 88, 94], ["nt changes", "OBSERVATION", 10, 20]]], ["The Greece-Saudi Arabia_2014 sequences clustered most closely with human derived MERS-CoV strains obtained in Jeddah and Makkah, Saudi Arabia, in April 2014.", [["human", "ORGANISM", 67, 72], ["MERS-CoV", "ORGANISM", 81, 89], ["Greece-Saudi Arabia_2014 sequences", "DNA", 4, 38], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["MERS-CoV", "SPECIES", 81, 89]]], ["MERS-CoV sequences recently obtained from dromedary camels in Saudi Arabia and Qatar also clustered with the Greece-Saudi Arabia_2014 sequences.ResultsSerology identified specific anti-MER-CoV IgM (titer 1/100) and IgG (titer 1/320) antibodies in the patient\u2019s serum sample.DiscussionThe present study describes the laboratory investigation of an imported MERS-CoV case in Greece.", [["serum sample", "ANATOMY", 261, 273], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["anti-MER-CoV IgM", "GENE_OR_GENE_PRODUCT", 180, 196], ["IgG", "GENE_OR_GENE_PRODUCT", 215, 218], ["patient", "ORGANISM", 251, 258], ["serum", "ORGANISM_SUBSTANCE", 261, 266], ["MERS-CoV", "ORGANISM", 356, 364], ["MERS-CoV sequences", "DNA", 0, 18], ["Greece-Saudi Arabia_2014 sequences", "DNA", 109, 143], ["anti-MER", "PROTEIN", 180, 188], ["CoV IgM", "PROTEIN", 189, 196], ["titer 1/100", "PROTEIN", 198, 209], ["IgG", "PROTEIN", 215, 218], ["titer 1/320) antibodies", "PROTEIN", 220, 243], ["patient", "SPECIES", 251, 258], ["MERS-CoV", "SPECIES", 356, 364], ["MERS-CoV sequences", "TEST", 0, 18], ["ResultsSerology", "TEST", 144, 159], ["CoV IgM", "TEST", 189, 196], ["titer", "TEST", 198, 203], ["IgG", "TEST", 215, 218], ["antibodies", "TEST", 233, 243], ["serum sample", "TEST", 261, 273], ["the laboratory investigation", "TEST", 312, 340]]], ["Discrepancy of the rRT-PCR results between specimens A and B may be due to different sampling techniques, although detection attributable to increasing viral load with infection progression cannot be ruled out for specimen B. Collection of additional specimens, particularly from the lower respiratory tract and at different time points over the disease course is highly recommended when there is strong clinical and epidemiological suspicion of MERS-CoV infection and initial results from upper respiratory tract specimens are negative or inconclusive.", [["specimens", "ANATOMY", 43, 52], ["specimens", "ANATOMY", 251, 260], ["lower respiratory tract", "ANATOMY", 284, 307], ["upper respiratory tract specimens", "ANATOMY", 490, 523], ["infection", "DISEASE", 168, 177], ["MERS-CoV infection", "DISEASE", 446, 464], ["B", "CELL", 59, 60], ["specimens", "CANCER", 251, 260], ["lower", "ORGANISM_SUBDIVISION", 284, 289], ["respiratory tract", "ORGANISM_SUBDIVISION", 290, 307], ["MERS-CoV", "ORGANISM", 446, 454], ["upper respiratory tract specimens", "CANCER", 490, 523], ["rRT", "DNA", 19, 22], ["MERS-CoV", "SPECIES", 446, 454], ["the rRT-PCR", "TEST", 15, 26], ["different sampling techniques", "TEST", 75, 104], ["increasing viral load", "PROBLEM", 141, 162], ["infection progression", "PROBLEM", 168, 189], ["specimen B. Collection of additional specimens", "TEST", 214, 260], ["the lower respiratory tract", "PROBLEM", 280, 307], ["MERS", "PROBLEM", 446, 450], ["CoV infection", "PROBLEM", 451, 464], ["upper respiratory tract specimens", "TEST", 490, 523], ["increasing", "OBSERVATION_MODIFIER", 141, 151], ["viral load", "OBSERVATION", 152, 162], ["infection", "OBSERVATION", 168, 177], ["lower", "ANATOMY_MODIFIER", 284, 289], ["respiratory tract", "ANATOMY", 290, 307], ["disease", "OBSERVATION", 346, 353], ["CoV", "OBSERVATION_MODIFIER", 451, 454], ["infection", "OBSERVATION", 455, 464], ["upper", "ANATOMY_MODIFIER", 490, 495], ["respiratory tract", "ANATOMY", 496, 513]]], ["Drosten et al. pointed out that up to 106 copies/mL of MERS-CoV RNA were present in lower respiratory tract specimens, whereas only small amounts of viral RNAs could be detected in upper respiratory tract specimens [8].DiscussionAccording to World Health Organization recommendations, partial sequencing of the RdRp and N genes is an acceptable alternative for confirmation of MERS-CoV infection [7].", [["lower respiratory tract specimens", "ANATOMY", 84, 117], ["upper respiratory tract specimens", "ANATOMY", 181, 214], ["MERS-CoV infection", "DISEASE", 377, 395], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 90, 107], ["specimens", "ORGANISM_SUBSTANCE", 108, 117], ["MERS-CoV", "ORGANISM", 377, 385], ["MERS-CoV RNA", "RNA", 55, 67], ["viral RNAs", "RNA", 149, 159], ["RdRp and N genes", "DNA", 311, 327], ["MERS-CoV", "SPECIES", 55, 63], ["MERS-CoV", "SPECIES", 377, 385], ["MERS", "PROBLEM", 55, 59], ["CoV RNA", "PROBLEM", 60, 67], ["lower respiratory tract specimens", "TEST", 84, 117], ["small amounts of viral RNAs", "PROBLEM", 132, 159], ["the RdRp", "TREATMENT", 307, 315], ["MERS", "PROBLEM", 377, 381], ["CoV infection", "PROBLEM", 382, 395], ["lower", "ANATOMY_MODIFIER", 84, 89], ["respiratory tract", "ANATOMY", 90, 107], ["small", "OBSERVATION_MODIFIER", 132, 137], ["amounts", "OBSERVATION_MODIFIER", 138, 145], ["viral RNAs", "OBSERVATION", 149, 159], ["upper", "ANATOMY_MODIFIER", 181, 186], ["respiratory tract", "ANATOMY", 187, 204]]], ["Although RT-PCR and partial gene sequencing methods are more time consuming, we found this approach to be very helpful in resolving our discrepant RT-PCR results.DiscussionDetection of MERS-CoV-specific antibodies in the patient\u2019s serum was consistent with recent MERS-CoV infection.", [["serum", "ANATOMY", 231, 236], ["infection", "DISEASE", 273, 282], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 185, 193], ["patient", "ORGANISM", 221, 228], ["serum", "ORGANISM_SUBSTANCE", 231, 236], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 264, 272], ["MERS-CoV-specific antibodies", "PROTEIN", 185, 213], ["patient", "SPECIES", 221, 228], ["MERS-CoV", "SPECIES", 264, 272], ["RT-PCR", "TEST", 9, 15], ["partial gene sequencing methods", "TREATMENT", 20, 51], ["MERS-CoV", "TEST", 185, 193], ["specific antibodies", "TEST", 194, 213], ["the patient\u2019s serum", "TEST", 217, 236], ["recent MERS", "PROBLEM", 257, 268], ["CoV infection", "PROBLEM", 269, 282], ["consistent with", "UNCERTAINTY", 241, 256], ["CoV infection", "OBSERVATION", 269, 282]]], ["Ideally, however, for serological confirmation of acute MERS-CoV infection, a second serum specimen taken two weeks or more after onset of illness should also be tested.DiscussionOur findings revealed a genomic subpopulation in the swab sample that possessed a unique amino acid substitution in S protein receptor-binding domain (RBD) as compared with other published human and camel sequences.", [["serum specimen", "ANATOMY", 85, 99], ["swab sample", "ANATOMY", 232, 243], ["MERS-CoV infection", "DISEASE", 56, 74], ["illness", "DISEASE", 139, 146], ["amino acid", "CHEMICAL", 268, 278], ["amino acid", "CHEMICAL", 268, 278], ["MERS-CoV", "ORGANISM", 56, 64], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["amino acid", "AMINO_ACID", 268, 278], ["S protein receptor-binding domain", "GENE_OR_GENE_PRODUCT", 295, 328], ["human", "ORGANISM", 368, 373], ["camel", "ORGANISM", 378, 383], ["S protein receptor-binding domain", "PROTEIN", 295, 328], ["RBD", "PROTEIN", 330, 333], ["human and camel sequences", "DNA", 368, 393], ["human", "SPECIES", 368, 373], ["MERS-CoV", "SPECIES", 56, 64], ["human", "SPECIES", 368, 373], ["serological confirmation", "TEST", 22, 46], ["acute MERS", "PROBLEM", 50, 60], ["CoV infection", "PROBLEM", 61, 74], ["a second serum specimen", "TEST", 76, 99], ["illness", "PROBLEM", 139, 146], ["a genomic subpopulation in the swab sample", "PROBLEM", 201, 243], ["a unique amino acid substitution", "TREATMENT", 259, 291], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["MERS", "OBSERVATION", 56, 60], ["CoV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74], ["genomic", "OBSERVATION_MODIFIER", 203, 210], ["subpopulation", "OBSERVATION_MODIFIER", 211, 224], ["acid substitution", "OBSERVATION", 274, 291]]], ["The above substitution was confirmed independently by two separate CDC laboratories, ruling out the possibility of its introduction during the RT-PCR.", [["The above substitution", "TREATMENT", 0, 22], ["the RT-PCR", "TREATMENT", 139, 149]]], ["The R511P substitution is located within a region (residues 484 to 567) of the MERS-CoV RBD that directly interacts with the dipeptidyl peptidase4 (DPP4) receptor on the host cell surface for viral attachment [9\u201312].", [["cell surface", "ANATOMY", 175, 187], ["R511P", "GENE_OR_GENE_PRODUCT", 4, 9], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["dipeptidyl peptidase4", "GENE_OR_GENE_PRODUCT", 125, 146], ["DPP4", "GENE_OR_GENE_PRODUCT", 148, 152], ["cell surface", "CELLULAR_COMPONENT", 175, 187], ["residues 484 to 567", "PROTEIN", 51, 70], ["MERS-CoV RBD", "PROTEIN", 79, 91], ["dipeptidyl peptidase4 (DPP4) receptor", "PROTEIN", 125, 162], ["MERS-CoV", "SPECIES", 79, 87], ["The R511P substitution", "TREATMENT", 0, 22], ["CoV RBD", "PROBLEM", 84, 91], ["the dipeptidyl peptidase4 (DPP4", "TREATMENT", 121, 152], ["viral attachment", "PROBLEM", 192, 208], ["CoV RBD", "OBSERVATION", 84, 91], ["host cell", "OBSERVATION", 170, 179], ["surface", "OBSERVATION_MODIFIER", 180, 187], ["viral attachment", "OBSERVATION", 192, 208]]], ["Recent mutagenesis studies indicated that alterations of key residues within that region, i.e., the D510A and the E513A, have been shown to significantly reduce both binding and viral entry efficiency [9, 13].", [["E513A", "GENE_OR_GENE_PRODUCT", 114, 119], ["D510A", "DNA", 100, 105], ["E513A", "DNA", 114, 119], ["Recent mutagenesis studies", "TEST", 0, 26], ["alterations of key residues", "PROBLEM", 42, 69], ["key residues", "OBSERVATION", 57, 69], ["viral entry efficiency", "OBSERVATION", 178, 200]]], ["The same studies indicated that the R511A substitution had little to no effect to the binding affinities of the RBD for DPP4.", [["DPP4", "GENE_OR_GENE_PRODUCT", 120, 124], ["RBD", "PROTEIN", 112, 115], ["DPP4", "PROTEIN", 120, 124], ["The same studies", "TEST", 0, 16], ["the R511A substitution", "TREATMENT", 32, 54], ["DPP4", "TEST", 120, 124]]], ["Further studies are needed to clarify whether the substitution of arginine to proline in the same position (R511P) identified in the present study had any functional implication.DiscussionPhylogenetic analysis revealed that the Greek strain was most closely related to Jeddah and Makkah strains circulating during the recent burst of MERS-CoV activity in the Arabian Peninsula [14].", [["arginine", "CHEMICAL", 66, 74], ["proline", "CHEMICAL", 78, 85], ["arginine", "CHEMICAL", 66, 74], ["proline", "CHEMICAL", 78, 85], ["arginine", "AMINO_ACID", 66, 74], ["proline", "AMINO_ACID", 78, 85], ["Greek strain", "ORGANISM", 228, 240], ["Makkah strains", "ORGANISM", 280, 294], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 334, 342], ["MERS-CoV", "SPECIES", 334, 342], ["Further studies", "TEST", 0, 15], ["arginine to proline", "TREATMENT", 66, 85], ["the present study", "TEST", 129, 146], ["Phylogenetic analysis", "TEST", 188, 209], ["the Greek strain", "PROBLEM", 224, 240], ["Makkah strains", "PROBLEM", 280, 294], ["burst", "OBSERVATION_MODIFIER", 325, 330]]], ["This was consistent with the assumption that the patient might have acquired the infection in the community or, alternatively, in a nosocomial-environment, as he had visited a local hospital in Jeddah repeatedly since the beginning of April 2014.", [["infection", "DISEASE", 81, 90], ["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["the infection", "PROBLEM", 77, 90], ["consistent with", "UNCERTAINTY", 9, 24], ["infection", "OBSERVATION", 81, 90]]], ["Moreover, the clustering of the Greek S and N ORFs with sequences from some dromedary camels was in accordance with recent findings, confirming the similarity between human and camel MERS-CoV sequences identified in the same geographical areas [15, 16].DiscussionThe ongoing outbreak of MERS-CoV suggests that the risk of importation of the virus in countries is expected to continue, although the number of incident cases has been steadily declining [1].", [["human", "ORGANISM", 167, 172], ["camel MERS-CoV", "ORGANISM", 177, 191], ["MERS-CoV", "ORGANISM", 287, 295], ["Greek S and N ORFs", "DNA", 32, 50], ["human and camel MERS-CoV sequences", "DNA", 167, 201], ["human", "SPECIES", 167, 172], ["camel", "SPECIES", 177, 182], ["human", "SPECIES", 167, 172], ["camel MERS-CoV", "SPECIES", 177, 191], ["MERS-CoV", "SPECIES", 287, 295], ["the Greek S and N ORFs", "PROBLEM", 28, 50], ["CoV sequences", "TEST", 188, 201], ["the virus", "PROBLEM", 337, 346]]], ["In that respect, fast and reliable laboratory confirmation is crucial for timely implementation of infection control measures to prevent secondary person to person transmission.", [["infection", "DISEASE", 99, 108], ["person", "SPECIES", 147, 153], ["person", "SPECIES", 157, 163], ["infection control measures", "TREATMENT", 99, 125], ["infection", "OBSERVATION", 99, 108]]]]}